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Abstract
The non-pathogenic actinomycete Micromonospora viridifaciens secretes a 
41kDa neuraminidase when colominic acid is used as an inducer and a 68kDa 
neuraminidase when milk casein is used. The X-ray crystal structure of the 41kDa form 
of the enzyme was solved by the technique of multiple isomorphous replacement and 
the structure of the 68kDa enzyme was solved using molecular replacement with 
weighted difference Fourier maps.
The 41kDa form of the enzyme has been refined to a resolution of 1.8A with a 
crystallographic R-factor of 17.3%. The enzyme exhibits the canonical (3-propeller fold 
found in influenza virus neuraminidase and the bacterial neuraminidases from 
Salmonella typhimurium and Vibrio cholerae. In addition the structure of the 41kDa 
enzyme complexed with the inhibitor 2-deoxy-2,3-dehydro-N-acetylneuraminic acid 
has been solved and refined to a resolution of 2.0A with a crystallographic R-factor of 
15.5%. The enzyme retains the same conserved active site residues found in the other 
neuraminidases, although there are subtle differences. In spite of a low sequence 
identity between the 41kDa form of the neuraminidase from M.viridifaciens and other 
neuraminidases, the overall fold of the enzyme is remarkably similar.
The 68kDa enzyme has been refined to a resolution of 2.5A with a 
crystallographic R-factor of 21.4%. In the 68kDa form of the enzyme, the catalytic 
domain is followed by a “linker” domain which has the immunoglobulin fold and a third 
domain which has high homology to the galactose binding domain of galactose oxidase 
from Dactylinm dendroides. The bacterium may have acquired these immunoglobulin 
and galactose binding modules from eukaryotes by horizontal gene transfer. The
galactose binding site of the 68kDa enzyme was established by collecting data from the 
complex and the structure of the 68kDa enzyme with bound galactose has been refined 
to a resolution of 2.5A with a crystallographic R-factor of 22.8%. Putative functions 
for the additional domains of the 68kDa enzyme are suggested and discussed.
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RESEC - Resections a given electron density map.
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DENZO - program by Otwinowski to process data collected on film and the image 
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XSCALE - program by Kabsch to merge data sets.
X2L* - converts hkl files to LCF format.
LCF2MTZ* - converts LCF format to MTZ format.
MTZUTILS* - combines two reflection files and can be used to edit columns, labels 
or titles.
MTZDUMP* - lists the header and reflections of an MTZ formatted reflection file. 
MTZTONA4* - converts MTZ files to NA4 ASCII format.
CAD* - combines and sorts a number of reflection files. It was used to convert data 
from one area of reciprocal space to another.
LOCAL - Local scaling of two data sets.
FFT* - performs the crystallographic fast Fourier transform.
PLUTO* - used to plot sections of Patterson maps.
VECSUM* - automated search for Patterson peaks.
VECREF* - Patterson space refinement of the heavy atom sites.
MLPHARE* - refines heavy atom paramters and calculates phases.
FHSCAL* - scales native to derivative data.
SIGMAA* - phase combination of isomorphous and calculated phases.
PEAKMAX* - searches for peaks in an electron density map.
SFALL* - calculates structure factors from an electron density map or atomic 
coordinates using the inverse FFT.
RSTATS* - scales F0 to Fc using least squares.
MOLSCRIPT - a drawing package.
RASTER 3-D - renders the output from MOLSCRIPT.
DSSP - determines the secondary structure of the protein from a set of atomic 
coordinates.
CONTACT* - lists the contacts between specified atoms in a structure.
GCG - University of Wisconsin Genetics Computer Group: a sequence analysis 
software package.
ALSCRIPT - program to improve the presentation of multiple sequence alignments, 
by Geoff Barton.
COMPOSER - molecular modelling software from Birkbeck. MNYFIT from 
COMPOSER was used here to perform structural superpositions.
WANG - algorithm by the aforementioned to perform solvent flattening of electron 
density maps.
SQUASH - density modification package. Can perform solvent flattening, histogram 
matching and uses Sayer’s equation to phase extend.
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Under investigation is the enzyme neuraminidase (or sialidase), from the 
non-pathogenic actinomycete Micromonospora viridifaciens. The terms sialidase 
and neuraminidase are generally interchangeable, since the enzyme hydrolyses the 
removal of sialic or N-acetyl neuraminic acid. A detailed account of this group of 
enzymes is given, emphasizing the pivotal role in nature which neuraminidases play, 
followed by some background to the organism from which the neuraminidase in 
question originates and the aims of the project
A brief history
The first neuraminidases to be discovered were from influenza virus and 
Vibrio cholerae in 1940. It was found that allantoic fluid from chick embryos 
infected with influenza virus agglutinated red blood cells in the cold. However, 
when the temperature of the cells was raised to 37 °C, the cells dispersed and could 
not be re-agglutinated with further virus. This suggested that the surface of the red 
blood cells contained a substrate for an enzyme in the virus, which was also the 
receptor for the virus itself. It was then also discovered that these virus receptors 
could be removed by an enzyme secreted by V.cholerae and the molecule split from
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the virus receptors was identified as sialic acid (Hirst, 1941; Gottschalk & Lind, 
1949). Thus, neuraminidase catalyses the cleavage of terminal sialic acid residues 
from glycoconjugates and oligosaccharides. The 9-carbon backbone common to all 
sialic acids is shown in fig. 1.1, with possible substitutions.
Fig. 1.1 Diversity in the sialic acids. Natural substitutions observed to date at C4 - 
C 9  are indicated. Various types of glycosidic linkage at R 3 ,  the generation of 
lactones at Ci, dehydro forms by eliminating R3 and anhydro forms generate 
additional diversity.
Ri = H, Acetyl (4,7,8,9), Lactyl (9), Methyl (8), Sulfate (8), 
Phosphate (9), Anhydro (4,8 or 2,7), Sialic acid (8,9),
Fucose (4), Glucose (8), or Galactose (4)
R2 = N-Acetyl, N-Glycolyl, Amino, Hydroxyl
R3 = Gal (3/4/6), GalNAc (6), GlcNAc (4/6) or Sialic acid (8/9) 
(Absent in 2,6 and 2,7 anhydro compounds)
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Sources of neuraminidase
Neuraminidases are ubiquitous in nature and are found in some viruses, 
pathogenic and non-pathogenic bacteria, some parasites and in all complex 
metazoans from starfish to humans. The best characterized neuraminidases are 
those from viral and to a lesser extent bacterial sources. A dendrogram showing the 
relationship in terms of sequence identity between the viral and non-viral 
neuraminidases is shown in fig. 1.2. As the grouping indicates, sequence identities 
are variable between the neuraminidases, being highest between the influenza virus 
B neuraminidases and lowest between the bacterial neuraminidases (table 1.1).
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Fig. 1.2 A dendrogram of the viral and non-viral neuraminidases. Grouping 
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(a) Influenza virus neuramindase
Influenza viruses can be divided into two classes, types A and B. Type A 
can be further subdivided into nine serologically distinct subtypes; N1-N9.
Influenza virus neuraminidase preferably cleaves the a2-3 linkage between the 
terminal sialic acid residue and the penultimate sugar. The role of neuraminidase in 
the life cycle of the virus is still not completely understood, however two main 
functions have been assigned to the enzyme. It is well established that there is a link 
between influenza virus infectivity and neuraminidase activity. Influenza virus 
neuraminidase aids virus penetration of host epithelial cells by removing sialic acids 
from mucin and thus lowering the viscosity. The neuraminidase also removes sialic 
acids from hemagglutinin, the second antigen on the surface of the influenza virus. 
Hemagglutinin is responsible for the attachment of virus to cells and for the 
penetration of the virus into the cell during the initial stages of infection. Removal 
of sialic acids from the hemagglutinin prevents self agglutination of infected host 
cells (Palese et al., 1974) and allows elution of virus progeny virus particles from 
infected cells, thus aiding infectivity (Gottschalk, 1966).
The inadequacy of vaccines against influenza virus, due to the rapid 
antigenic drift and shift that the viral antigens undergo (Murphy & Webster, 1990) 
has prompted the search for inhibitors against neuraminidase. The first inhibitor to 
be discovered was a synthetic derivative of sialic acid called Neu5Ac2en (fig. 1.3), 
or 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA), which is believed to 
represent a transition state analogue (Meindl & Tuppy, 1969). Many other 
analogues of DANA have now been synthesized (Meindl et al., 1974; Flashner et
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al., 1983; Glanzer et al., 1991), but none have Kj values less than micromolar, or 
show significant activity in vivo. However with the advent of high resolution native 
and some substrate/inhibitor-bound crystal structures of influenza virus A 
neuraminidases of subtypes N2 (Varghese et al., 1983) and N9 (Tulip et al., 1991), 
as well as influenza virus B neuraminidases of strain B/Lee/40 (Janakiraman et al., 
1994) and B/Beijing/1/87 (Burmeister et al., 1992), rational drug design has 
become possible. The rational design of a specific inhibitor of influenza virus 
neuraminidase will be discussed in Chapter 8.
The structure of influenza virus neuraminidase
The viral neuraminidase is a homo-tetramer of molecular weight 240kDa. It 
consists of a globular box like-head where the enzymatic activity resides, attached 
to a hydrophobic stalk which anchors the enzyme in the membrane. The 
neuraminidase heads can be released by digestion with pronase or trypsin and can 
be crystallized. Sequence identities range from as low as 25% between subtypes, to 
70% or more within a subtype. Identities between viral and non-viral 
neuraminidases can be as low as 16% (table 1.1). Despite these variable sequence 
identities, all neuraminidase structures characterized to date possess the canonical 
neuraminidase (3-propeller fold, which consists of six four stranded antiparallel p- 
pleated sheets wrapped around the blades of a propeller.
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Table 1.1 Sequence identities between viral and non-viral neuraminidases.
% mhc
89
T.cruzi V.cholerae mv1 st2 N8 N9 N2 B/Beijing B/Lee
mhc g93 100 21.8 25.7 33.4 28.3 19.1 17.2 17.4 16.7 18.6
T.cruzi 21.8 100 19.9 21.8 31.6 17.4 15.2 15.3 15.1 14.6
V.cholerae 25.7 19.9 100 26.0 26.9 16.9 17.0 19.7 18.0 17.7
mv1 33.4 21.8 25.9 100 19.2 16.2 15.4 16.2 18.3 19.8
st2 28.3 31.6 26.9 19.2 100 18.2 15.1 16.9 17.5 17.2
N8 19.1 17.4 16.8 16.2 18.2 100 42.3 47.5 33.8 33.6
N9 17.2 15.2 17.0 15.4 15.1 43.0 100 45.6 29.2 29.6
N2 17.4 15.3 19.8 16.2 16.9 47.5 45.6 100 31.6 29.4
B/Beijing 16.7 15.1 18.0 18.3 17.5 33.8 29.2 31.6 100 94.4
B /Lee 18.6 14.6 17.7 19.8 17.2 33.6 29.6 29.4 94.4 100
1 M.viridifaciens neuraminidase
2 S.typhimurium neuraminidase
3 MHC G9 is a neuramindase found in the human major histocompatibility 
complex (Duncan Campbell and Caroline Milner - personal communication)
Putative calcium ions have been located in the reported X-ray structures of 
influenza virus neuraminidases. The calcium ion is believed to have a stabilizing 
effect on the enzyme’s active site, although since the presence of calcium is not 
essential for enzyme activity, it does not have a direct catalytic role (Burmeister et 
a l , 1992).









(b) The bacterial neuraminidases
Neuraminidases are also widely distributed in bacterial species. Bacterial 
neuraminidases have varying molecular weights and may be broadly classified into 
large, or high molecular weight (e.g. V.cholerae) and small, or low molecular 
weight (e.g. S.typhimurium). High activities are common and substrate specificity is 
broader than for the influenza viral neuraminidases, including cleavage of a2-3, a2- 
6, and less frequently a2-8 linkages. Bacterial neuraminidases are known to have a 
nutritional role as well as being implicated in pathogenesis.
Structure of the bacterial neuraminidases
The structures of the small bacterial neuraminidase from S.typhimurium 
(Crennell et al., 1993) and the large bacterial neuraminidase from V.cholerae 
(Crennell et al., 1994) have been reported. Despite the low sequence identity 
exhibited between the bacterial and viral enzymes (~ 15%, table 1.1), both the 
bacterial neuraminidase structures show a high similarity in the overall fold and in 
the spatial arrangement of catalytic residues. All the bacterial neuraminidases 
possess a number of conserved sequence motifs, called Asp-boxes. These have the 
sequence Ser/Thr-X-Asp-[X]-Gly-X-Thr-Trp/Phe and are found in spatially 
conserved positions between the third and fourth strands of the (3-sheets. The 
function of Asp-boxes remains unknown, but they may be involved in secretion or 
protein folding.
The first structure of a bacterial neuraminidase to be solved was that from 
S.typhimurium. S.typhimurium neuraminidase is mainly p-sheet, possessing the
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canonical (3-propeller fold, and has two small a-helices. There is one disulphide 
bond between the innermost (3-strands of the first and second sheets. Although the 
fold of the enzyme is identical to that of the influenza viral neuraminidases, there 
are major differences in the lengths of the loops and P-strands. The neuraminidase 
from S.typhimurium possesses four conserved Asp-box motifs in between the third 
and fourth strands of the first four sheets.
The second structure of a bacterial neuraminidase to be reported was that 
from V.cholerae. The neuraminidase from V.cholerae belongs to the class of large 
bacterial neuraminidases and has a molecular weight of 83kDa. Again the enzyme is 
mostly P-sheet, with 5 small a-helices. In addition to the typical canonical p- 
propeller neuraminidase domain, the enzyme also has two lectin-like domains 
(wings) which flank the former domain. Each lectin-like domain consists of a 
sandwich formed from two sheets of seven and six antiparallel p-strands, having a 
topology most like that of the legume lectins. The purpose of these wings in the 
pathogenicity or life-cycle of V.cholerae is unknown, and the wings do not retain 
any of the carbohydrate binding residues found in the lectins. However the 
carbohydrate binding sites of the lectins are located on the concave surface of the 
fold and the equivalent surfaces in V.cholerae neuraminidase are solvent exposed, 
thus suggesting that the wings do recognize a ligand (Crennell et al., 1994). 
V.cholerae neuraminidase has four Asp-boxes, together with a further Asp-box 
which deviates from the consensus sequence. In contrast to the small bacterial 
neuraminidases the enzyme requires Ca2+ for activity.
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Non-pathogenic neuraminidases
The terminal non-reducing position of sialic acids in sialo-glycoconjugates 
requires that the sialic acid must be removed before metabolism of the remaining 
oligosaccharide chain can occur. Many non-pathogenic neuraminidases function in 
symbiotic relationships at mucosal surfaces, such as the oral cavity and the human 
large intestine. For some neuraminidases, no role has yet been defined, e.g. the soil 
bacteria Arthrobacter sp. and M.viridifaciens. However they may simply fulfil part 
of the nutritional requirement of the bacterium, metabolizing the sialic acid as a 
carbon and energy source. In the human large intestine, these bacteria belong to the 
enteric bacteria and comprise the most abundant anaerobes, e.g. Bacteriodes sp., 
facultative anaerobes such as E.coli and Enterococcus faecalis strains, and a group 
of mucin oligosaccharide-degrading bacteria including Ruminococcus and 
Bifidobacterium sp. which are capable of completely degrading the glycoproteins 
present in the mucus at the surface of the normal mucosa (Hoskins et al., 1985). A 
role for these enzymes in providing an energy source for the bacteria through 
mucus degradation has been demonstrated (Hoskins et al., 1985). However a 
balance is required between synthesis of the mucin, which provides a defence 
mechanism and the degradation to provide a source of energy. O-acetylation of 
sialic acids is known to retard the rate of action of bacterial neuraminidases 
(Corfield et al., 1986, 1992) and colonic mucins contain a typically high sialic acid 
O-acetylation pattern. In addition, the presence of an O-acetyl sialic acid esterase in 
many human enteric bacterial strains provides additional regulation. A scheme 
depicting this method of regulation of sialic acid degradation in human colonic 
bacteria is illustrated in fig 1.4.
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Fig.1.4 Regulation of sialic metabolism in human colonic bacteria. More than two 
O-acetyl esters on a sialic acid results in retardation of the rate of catalysis by the 
neuraminidase. A specific O-acetyl esterase removes the acetyl esters, thus 
facilitating neuraminidase action.
O - ACETYL ESTERASE 




TRANSPORT & METABOLISM IN THE BACTERIAL CELL
A further example of the nutritional role of neuraminidases has been shown 
for S.typhimurium LT2 (Vimr & Hoyer, 1992). The nan H gene coding for the 
neuraminidase was only found in the subgenus 1 isolate for LT2. Thus, the 
presence of the neuraminidase is not necessary for pathogenesis in this genus 
(Hoyer et al., 1992). A S.typhimurium mutant, deficient in neuraminidase was used 
to compare the growth of the wild type and mutant strains using sialyl oc(2,3)- 
lactose as the sole carbon source. Salmonella strains cannot use lactose as a carbon 
source and sialic acid must be released first before it can be taken up and 
metabolized by the bacteria. As a result, the wild type bacterium was able to grow 
on the sialyl-lactose medium, but the neuraminidase negative mutant was not (Vimr 
& Hoyer, 1992).
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Neuraminidases associated with pathogenicity
Neuraminidase is one of the many hydrolytic enzymes often associated with 
bacterial invasion of the host Some of the diseases associated with neuraminidase 
activity, such as meningitis and glomerulonephritis are localized to defined sites 
where they cause damage. Others such as gas gangrene and peritonitis, exhibit a 
much wider pattern of colonization and bacteria are found regularly in the 
circulation. A summary of the more important infectious diseases associated with 
neuraminidase activity are listed in table 1.2.
Table 1.2 Disease related neuraminidases and their major site(s) of infection.
Disease Bacteria Site Found in 
blood?




























Otitis media Streptococcus middle ear no




Because of the involvement of sialic acids in cellular functions, enzymic 
removal by neuraminidase leads to marked differences in the biological behaviour 
of cells and molecules; sometimes resulting in pathogenesis. Five main functions for 
sialic acids can be summarized:
1. As a result of their strong negative charge, sialic acids are involved in the binding 
and transport of positively charged compounds and in aggregation via Ca2+ bridges, 
or disaggregation by repulsive effects in cells.
2. Sialic acids influence the conformation of glycoproteins, which is important for 
the correct arrangement of glycoprotein molecules in cell membranes, for the 
resistance of glycoproteins to proteases and for the activity of glycoprotein 
enzymes.
3. N- and O- acetylated sialic acids are antigenic determinants in various 
mammalian and microbial systems (Schauer, 1983). In addition, sialic acids 
contribute to the specificity of blood group substances (Roelcke, 1984).
4. Sialic acids are essential components of receptors, e.g. for peptide hormones, 
toxins and viruses (Paulson et al., 1984). Infection of cells by these microorganisms 
is exclusively dependent on the presence of sialic acids on cell membranes.
5. Sialic acids prevent recognition of receptors by the corresponding ligands, or 
vice versa, and recognition of antigenic sites by components of the immune defence 
system. The role of sialic acids as biological masks is possibly the most important 
role of sialic acids (Schauer et al., 1984) and will be discussed in more detail.
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Removal of biological masks by neuraminidases associated with pathogenicity
A glycoprotein layer rich in sialic acids acts as an immunobarrier between 
mother and embryo. Suppression of antigenicity by sialic acids appears to be a 
general feature of molecules and cells and partial loss of these sugars has been 
proposed as a cause of autoimmune disease (Schauer, 1982; Reutter et al., 1982; 
Kottgen et al., 1979). Tumour cells have often been observed with highly sialyated 
surfaces and are thus protected from immune defence. This may contribute to the 
spread of the tumour. There are numerous other examples of sialic acids acting as 
biological masks, the removal of which can lead to various disease states. These 
include decreasing the reactivities of IgG with the Fc receptor of human T 
lymphocytes; cytotoxic complement-dependent factors against autologous, invasive 
human bladder tumour cells; killer cells; some receptors for hormones or drugs; and 
the binding of rabbit blood platelets to endothelial cells (Schauer et al., 1984). Two 
examples of disease related to neuraminidase action are discussed in detail:
1. Cholera. V.cholerae produces a potent neuraminidase which may play a role in 
the pathogenicity of the bacterium. Gangliosides are carbohydrate-rich 
sphingolipids that contain at least one sialic acid. The oligosaccharide chain is 
linked to ceramide by a glucose residue. The action of V.cholerae on cell surface 
gangliosides yields G mi gangliosides as a product because the galactose-linked 
sialic acid cannot be released by the enzyme (Venerando et al., 1982). G mi 
gangliosides consist of a galactose p-1,3 linked to N-acetylgalactosamine, which is 
p-1,4 linked to a further galactose moiety, which in turn is a-2,3 linked to N-acetyl 
neuraminic acid and p-1,4 linked to glucose. The oligosaccharide chain ends with
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ceramide linked via the glucose. G mi then acts as a receptor for the cholera 
enterotoxin at the mucosal cell surface, facilitating its penetration (Muller, 1976; 
Galen et a l., 1992).
2. Septicaemia. Strains of Streptococcus, pneumococcus, corynebacteria and 
Bacteriodes are amongst the many neuraminidase-producing bacteria which are 
primary agents in septicaemia. Analysis of the serum glycoproteins from patients 
with septicaemia due to Streptococcus sanguis strains showed that sialic acid had 
been lost. However the association of virulence with neuraminidase activity remains 
unclear. No requirement of neuraminidase as a virulence factor has been 
demonstrated, although a high-virulence clone of group B type III Streptococcus 
has been identified which produces elevated levels of extracellular neuraminidase 
(Musser et a l., 1989).
In summary, individual examples of a nutritional role, as in S.typhimurium 
LT2 (Vimr & Hoyer, 1992), or the absence of a nutritional role, as in P.aeruginosa 
(Cacalano et a l., 1992), may imply that combined roles for neuraminidase are likely 
to apply elsewhere. In this way, the bacteria can create an energy source, can 
overcome host defensive mechanisms and can create binding sites for colonization. 
A nutritional role may thus be considered as a real function of neuraminidase in 
both pathogenic and non-pathogenic bacteria.
(c) Mammalian neuraminidases
Neuraminidases from mammalian sources have been implicated in several 
important metabolic processes, such as the catabolism of gangliosides and
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glycoproteins (Tulsiani & Carubelli, 1970; Usuki et al., 1988a), the developmental 
modelling of myelin (Saito & Yu, 1992), the regulation of cell proliferation (Usuki 
et al., 1988b) and the clearance of glycoproteins from the serum (Ashwell & 
Morell, 1974). An important potential role for endogenous neuraminidases is in 
regulation of cell surface sialyation. It has been well documented that how a cell is 
seen by its external environment is determined in a large part by cell surface sialic 
acid (Whiteheart et al., 1990). There is indirect evidence to support this role for 
cellular neuraminidases. A decrease in sialic acid with no consistent alterations in 
sialyltransferase has been found in Rous sarcoma virus-transformed chick embryo 
fibroblasts (Spataro et al., 1975). Among various other enzymes involved in the 
turnover of sialic acids, neuraminidase was the only enzyme whose activity was 
altered in the virally transformed cells and the changes were correlated with the 
decrease in cellular sialic acid content. An increased level of neuraminidase activity 
has also been frequently observed in association with a decreased extent of cell 
surface sialyation in response to drug treatment (Sodhi & Prasab, 1985), during cell 
differentiation (Nojiri et al., 1982), or activation (Landolfi et al., 1985; Taira & 
Nariuchi, 1988). However whether these changes in neuraminidase activity are 
instrumental in the reported fluctuations in cell surface sialyation remains to be 
ascertained. Most cellular forms of the enzyme have not been well characterized at 
the molecular level and at present there is no crystal structure for a mammalian 
neuraminidase. This is due, in part, to the relatively low amounts found in all tissues 
and cell types. In addition, many forms of mammalian neuraminidase are extremely 
labile or tightly membrane associated. The enzyme has been localized in the 
lysosomal matrix (Tulsiani & Carubelli, 1970; Miyagi et al., 1990), the lysosomal
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membrane (Miyagi & Tsuiki, 1984; Zeigler et al., 1989; Sagawa et al., 1990), the 
plasma membrane (Sagawa et al., 1990), the myelin membrane (Saito et al., 1992) 
and the cytosol (Miyagi & Tsuiki, 1985; Tulsiani & Carubelli, 1970). To date, at 
least five distinct mammalian enzyme forms have been identified, each with 
different kinetic properties and substrate specificities. The enzyme from Chinese 
hamster ovary cells has been cloned, sequenced and expressed (Ferrari et al., 1994) 
and the amino acid sequence deduced. The amino acid sequence has no significant 
identity with any other mammalian protein, or indeed other microbial 
neuramindases. Since the bacterial neuraminidases have low sequence identity 
(table 1.1), in the order of only ~30%, this is not surprising. The mammalian 
sequence does however contain two Asp-box motifs. As detailed in Chapter 8, 
Asp-boxes have the consensus sequence Ser/Thr-X-Asp-[X]-Gly-X-Thr-Trp/Phe, 
are of unknown function and appear to be conserved across the bacterial 
neuraminidases.
(d) The Trans-sialidase (neuraminidase) family of Trypanosoma Cruzi
Protozoan parasites of the genus Trypanosoma express a unique sialic acid 
metabolising enzyme, called a trans-sialidase. Trans-sialidase catalyses the transfer 
of sialic acids from host glycoconjugates to receptor molecules of the parasite 
plasma membrane. The preferred sialic acid donors are sialyl a-2,3 linked to (3- 
galactosyl residues on glycoproteins, glycolipids and oligosaccharides 
(Vandekerckhove et al., 1992). The enzyme is expressed during infectious stages 
of the life cycle of the human pathogen Tiypanosoma cruzi and in the procyclic 
forms of Trypanosoma brucei. The enzyme from both trypomastigotes is the
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subject of much interest, due to the pathogenic nature of the organisms. T.cruzi is 
the causative agent of Chagas’ disease in Central and South America. T.brucei is 
the causative agent of sleeping sickness in man and nagana in game and domestic 
animals in Africa. However the trans-sialidase is only found in procyclic 
trypomastigotes of T.brucei and not in the mammalian stage bloodstream form.
Trans-sialidase structure
The native and purified enzyme forms multimeric aggregates of molecular 
mass >400kDa that migrate as multiple bands ranging from 100 to 220kDa in SDS- 
PAGE upon denaturation (Pereira et al., 1991; Schenkman et al., 1992). The bands 
differ in terms of their number and relative molecular weight depending on the 
strain of the parasite (Pereira et al., 1991). The enzyme is linked to the membrane 
in the parasite by a glycosyl phosphatidylinositol (GPI) anchor. The enzyme is 
released from trypanosomes by bacterial phospholipase C (Jazin et al., 1991; 
Rosenberg et al., 1991). Native trans-sialidase is formed by two separate domains, 
a conserved segment in the N-terminus containing the catalytic site and a 
heterogeneous region in the C-terminus necessary for enzyme oligomerization or 
aggregation (fig. 1.5).
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Fig. 1.5 Model of T.cruzi epimastigote (a) and trypmastigote (b). The 
epimastigote form of the trans-sialidase is monomeric, whereas the trypmastigote is 
multimeric. The two foms possess a similar catalytic domain, but the trypmastigote 
enzyme has an additional domain at the carboxy terminus composed of the 12 
amino acid repeats responsible for oligomerization.
All members of this family characterized so far have retained in the same 
positions three conserved Asp-boxes and a Fn3 domain containing a degenerate 
Asp-box and a highly conserved sequence of unknown function, VTV X NV X 
LYNR, located downstream of the catalytic domain.
At present there is no crystal structure for a trans-sialidase. However the 
T.cruzi trans-sialidase has a sequence identity of 31% with the neuraminidase from
S.typhimurium , for which the crystal structure is known (Crennell et a l., 1993). In 
addition, the catalytic residues identified in the S.typhimurium  enzyme are 
conserved in the trans-sialidase, as are the positions of the first three Asp-boxes.
Catalytic
domain
12 amino acids repeats
Mem bran«
(a) Epimastigote trans-sialidase (b) Trypomastigote trans-sialidase
19
It has been suggested that the trans-sialidase aids invasion of the target cell 
by the enzyme possessing a lectin-like activity towards the cellular and extracellular 
sialic acids. The enzyme will then function as a poor neuraminidase and the parasite 
may bind to rather than remove the host cell sialic acid. In support of this idea, the 
purified trans-sialidase inhibits cell invasion when added to the incubation medium 
(Ming et al., 1993).
To fully resolve many of the unanswered questions regarding the 
Trypanosoma trans-sialidases such as catalytic mechanism, a high resolution crystal 
structure will undoubtedly be necessary.
(e) Hemagglutinin neuraminidase
The paramyxoviruses are a group of negative stranded, enveloped, RNA- 
containing viruses that include Newcastle disease virus, mumps virus and the 
parainfluenza viruses (including Sendai virus, parainfluenza virus 3 and simian virus 
5) (Kingsbury et al., 1978). There are two types of spikes protruding from the 
virion membrane of paramyxoviruses. These are the fusion protein (F) and 
hemagglutinin neuraminidase (HN) glycoprotein spikes. Unlike the influenza virus, 
where the neuraminidase and hemagglutinin activities are carried by separate 
glycoproteins, the paramyxoviridae carry a bifunctional molecule; hemagglutinin 
neuraminidase.
The Dual functions of hemagglutinin neuraminidase
Hemagglutinin neuraminidase carries out the opposite functions of 
attachment to sialic acid containing cellular receptors and release from the same
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moiety, catalysed by the neuraminidase activity associated with the protein 
(Choppin & Scheid, 1980). Following exposure of a hydrophobic sequence by 
proteolytic cleavage, the F protein mediates both virus-cell and cell-cell fusion (Hsu 
et al., 1981; Scheid & Choppin, 1974). For many of the paramyxoviruses, including 
Newcastle disease virus, participation of the hemagglutinin neuraminidase spike is 
also necessary for membrane fusion. The hemagglutinin neuraminidase mediates 
attachment to cellular receptors and it has been shown that mutations in the 
hemagglutinin neuraminidase that influence the strength of its interaction with 
cellular receptors also influence the extent of syncytium formation (Iorio & 
Glickman, 1992).
Structural studies of hemagglutinin neuraminidase
At present there is no three-dimensional structure available for a 
hemagglutinin neuraminidase. However, considerable information is available about 
structure-function relationships of the enzyme in this genus. Ultrastructural and 
biochemical evidence exists that Sendai virus hemagglutinin neuraminidase 
molecules exist as disulphide-bonded dimers and tetramers on the virion surface 
(Markwell & Fox, 1980; Thompson et al., 1988). These homomultimers will 
presumably be able to carry out their functions with greater efficiency than could 
monomers. Extensive comparisons of the predicted amino acid sequences of a 
number of hemagglutinin neuraminidases have now been made following the 
elucidation of the primary sequences of the enzyme from representatives including 
Newcastle disease virus, mumps virus, Sendai virus and parainfluenza virus 
(Morrison & Portner, 1991). Colman et al. have proposed a model for the
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hemagglutinin neuraminidase three dimensional structure (Colman et a l., 1993). 
This model is based on the identification of invariant amino acids among 
hemagglutinin neuraminidases which have counterparts in the enzyme active site of 
influenza virus neuraminidase. The model is broadly similar to that of the influenza 
virus neuraminidase and has the canonical P-propeller fold.
The Enzyme in question
Of the genus Micromonospora, M.viridifaciens shows the highest 
neuraminidase enzymatic activity (Aisaka & Uwajima, 1987). The neuraminidase 
from M.viridifaciens is a typical inducible enzyme. When colominic acid is used as 
an inducer, a soluble 41kDa neuraminidase is secreted, however when milk casein 
is used a higher molecular weight 68kDa soluble neuraminidase is secreted 
(Sakurada et al., 1992). Neuraminidase from M.viridifaciens is monomeric, as with 
the other bacterial neuraminidases that have been characterized and possesses 5 
typical Asp-boxes. The neuraminidase MHC G9, a human enzyme from the major 
histocompatibility complex has highest sequence identity with M.viridifaciens 
neuraminidase (table 1.1), although the neuraminidase from C.perfringens has 
many similarities with M.viridifaciens neuraminidase. Both have similar methods of 
expression regulation, some catalytic properties are similar and the deduced 
processing site of M.viridifaciens neuraminidase agrees with the C-terminal end of 
C.perfringens neuraminidase when the two sequences are aligned by their 
homology (Aisaka et al., 1991; Nees e t a l ,  1975). The structures of 
neuraminidases from non-pathogenic bacteria, including M.viridifaciens, have not 
been characterized until now. The enzyme has a broad range of specificity with a
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high activity; in the range of 200 units/mg protein (Aisaka et al., 1991); which is 
comparable to that for C.perfringens (150-500 units/mg) (Cassidy et a I., 1965; 
Bouwstra etal., 1987; Drzeniek, 1972) and V.cholerae (133 units/mg) (Drzeniek, 
1972). The enzyme has its maximum activity at pH 5.0 when colominic acid or 
NANA-lactose was used as substrate (pH optimum for bacterial neuraminidases lies 
in the range 4.5-6.5 (Drzeniek et al., 1972)). The neuraminidase activity has 
previously been shown to reside in the N-terminal 41kDa portion of the enzyme 
(Sakurada et al., 1992), however the function of the remaining 27kDa is unknown. 
The precise role of the enzyme in cell metabolism remains to be established. Table
1.3 summarizes some of the differences between the neuraminidase from 
M.viridifaciens and other microbial species.
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Table 1.3 Comparison of the properties of some microbial neuraminidases. 
Molecular weights were determined by three methods:a by gel filtration b by SDS- 
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The Organism - Micromonospora viridifaciens
The neuraminidase studied in this project is produced by the non-pathogenic 
actinomycete Micromonospora viridifaciens. Actinomycetes are a group of 
unicellular gram-positive bacteria that are characterized by the formation of 
branching filaments. Micromonosporas occur both in soil and in fresh water, but
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the majority are found in the latter. Both of these members of the genus are strict 
anaerobes and many of them can utilize polysaccharides such as cellulose, chitin 
and xylan as carbon energy sources. Anaerobic, cellulose-fermenting species of 
Micromonospora have been isolated from the gut contents of termites and are the 
only members of this group capable of fermentation. Micromonosporas are 
members of the actinomycetes known as euactinomycetes. These develop only in 
the mycelial state and they reproduce through the formation of unicellular spores.
The Micromonospora strains are of significant industrial interest, due to 
their ability to produce antibiotics. Antibiotics produced by this genus include 
gentamicins (Maehr & Schaffner, 1967), sagamicins (Okachi et a /., 1974), 
sisomicins (Weinstein et a l., 1970) and fortimicin A (astromicin) (Nara et a l.,
1977). As a consequence an efficient gene cloning strategy has been developed for 
Micromonospora strains (Hasegawa et a l., 1991). However despite the interest in 
this genus, relatively little is known about the physiological and biochemical 
properties of Micromonospora strains, in particular M.viridifaciens.
Aims of the project
The aim of this project was to solve the three dimensional structures of both 
the 41kDa and 68kDa forms of the neuraminidase from the bacterium 
Micromonospora viridifaciens. Ideally the structure of the enzyme-inhibitor 
complex was also to be solved in order that detailed structural comparisons could 





In order to obtain protein crystals which are of as high a quality as possible, 
much effort must be put into purifying the protein in question to a high degree of 
homogeneity. Protein impurity is often a cause for the failure of proteins to 
crystallize successfully (Abergel et al., 1991). The purification strategy for both 
forms of the enzyme was based on a protocol developed by Taylor et al., (1992), 
utilizing fplc.
Obtaining protein crystals suitable for X-ray diffraction studies is still one of 
the major rate determining steps in the solution of a crystal structure and the 
technique of crystallization is still regarded by many as an art rather than a science. 
However, if a high resolution crystal structure is to be obtained, one must persist in 
their efforts to achieve good quality protein crystals, which diffract to a high 
resolution. Firstly the crystals should be large, since the intensity of the diffraction 
pattern is directly proportional to the volume of the crystal within the limits of 
absorption effects and secondly they should be fairly robust, so as to allow 
extensive data collection without rapid degradation of the crystal due to X-ray 
damage.
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However at present, we have a relatively poor understanding of the 
phenomena surrounding macromolecular crystallization and therefore we must 
resort to more empirical methods. This involves screening as many different 
conditions as possible to search for the optimum crystallization condition for a 
given protein. However the number of possible solutions to be tested is so great 
that an exhaustive search would be impractical (McPherson, 1982). Hence a sparse 
matrix of screening conditions, which samples a large range of buffers, pH, 
additives and precipitants is often used initially (Jancarik & Kim, 1991) to find 
approximate crystallization conditions.
Crystal growth
Crystals grow from a supersaturated solution, since the system must be in a 
non-equilibrium to provide the thermodynamic driving force for crystallization. In 
order to achieve the limited degree of supersaturation required for crystallization, 
several objectives must be met. The first is to deprive the protein molecules of 
enough water molecules to disrupt their hydration shell; whilst decreasing the 
effective electrostatic shielding between the macromolecules. These factors tend to 
induce phase separation and force the system towards a new free energy minimum. 
This maximizes attractive interactions and if the point of inadequate solvation is 
reached slowly enough the macromolecules are allowed sufficient opportunity to 
order themselves in a crystalline lattice. Modification of the solvent system, such as 
by the addition of precipitants, can encourage the process of supersaturation by 
guiding the system very slowly towards a state of minimum solubility. However
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due to the complex and rather unpredictable behaviour of macromolecules, as a 
result of their polyvalent surface character, varied shapes and dynamic properties, 
the correct degree of supersaturation for a given protein is not always easy to 
achieve. If a protein does prove difficult to crystallize, then a likely cause may be 
protein impurity, or microheterogeneity in the protein sample. Since crystals are 
essentially composed of perfect symmetry and periodic translational relationships 
between the molecules in the lattice, the introduction of impurities will result in 
inhibition of crystal growth since the non-uniform protein units will not be able to 
enter the crystal properly and will not bear proper correspondence to their 
neighbours. If early inhibition of crystal growth does present a problem, then a 
possible method of overcoming this is by the technique of seeding. Macroseeding 
involves transferring the crystal from the initial drop through a series of drops not 
containing protein, each containing increasing concentrations of precipitant. With 
successive transfers, any impurities on the surface of the crystal that are preventing 
continued crystal growth are hopefully removed and the crystal can then be 
transferred to a fresh drop containing protein and a decreased concentration of 
precipitant relative to the previous drop, determined by experience. Microseeding 
involves removing microseeds from a trial which may then provide nucleation sites 




There are various methods employed in the crystallization of biological 
macromolecules, including the growth of crystals in gels, the use of microdialysis, 
sitting drop and hanging drop vapour diffusion methods. The same basic principles 
outlined above are employed in all cases, and varying degrees of success have been 
recorded. Gel matrices have been found to suppress nucleation, reduce the rate of 
growth and generally lead to higher quality crystals with enhanced stability 
(Cudney et al., 1994), Microdialysis has the advantage that by liquid-liquid 
diffusion through a semi-permeable membrane, a protein solution can be exposed 
to potential crystal producing conditions without actually altering directly the 
mother liquor. In addition, because the rate of change of substituents in the mother 
liquor is proportional to the gradient of concentrations across the membrane, the 
nearer the system approaches equilibrium, the more slowly it changes (McPherson, 
1989). However, the vapour diffusion methods are still the most widely employed 
crystallization techniques today. Hanging drop vapour diffusion was the method 
implemented here, and as the name implies, uses vapour phase equilibration. A 
droplet of mother liquor, mixed with a droplet of the protein sample, is placed on a 
siliconized cover slip, inverted and placed over a tissue culture well, containing the 
precipitating solution. The cover slip is sealed with silicone vacuum grease. The 
transport of water through the vapour phase between the microdrop and the 
reservoir results in the protein concentration in the microdrop slowly coining to 
super saturation. Seeding techniques in the hanging drop are outlined as in the 
section on Crystal Growth.
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Purification of 41kDa M.viridifaciens neuraminidase
Crystals of the 41kDa M.viridifaciens neuraminidase had previously been 
grown by Elizabeth Dineley from protein purified from a culture filtrate of 
M.viridifaciens. The gene for the enzyme was later cloned (Sakurada et al., 1992) 
and the crude recombinant protein in a freeze-dried form (a generous gift from 
Mamoru Hasegawa, Kyowa Kogyo Co. Ltd., Tokyo, Japan) was used as the 
starting material in order to repeat the purification and obtain further crystals.
The recombinant protein was first dissolved in lOmM Tris-HCL buffer, pH 
8.0. This sample was run down an fplc Mono-Q anion exchange column, also 
equilibrated with lOmM Tris-HCL pH 8.0 and eluted with a NaCl gradient from 0 
to 0.2M. 1ml fractions judged to contain only/mostly the 41kDa protein by SDS 
PAGE (Laemmli, 1970) were pooled and then dialysed extensively against lOmM 
Tris-HCL pH 8.0.
The dialysed sample was then concentrated by spinning through a microsep 
concentrator (30K cut-off) until the desired volume was reached to give a protein 
concentration of approximately lOmgml"1. The concentrate was determined to be 
nearly 100% pure by SDS-PAGE (Fig. 2.1). A typical purification table is shown in 
Table 2.1.
Purification of 68kDa M.viridifaciens neuraminidase
The crude protein used as the starting point for the purification was an 
ammonium sulphate precipitation extract (kindly donated by Dr T. Uwajima, 
formerly of Kyowa Kogyo Co. Ltd., Tokyo, Japan), which was dissolved in lOmM
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Tris-HCL at pH 8.0. The sample was then centrifuged at 6,000 rpm for about 10 
minutes and the supernatant dialysed overnight against lOmM Tris-HCL pH 8.0, to 
ensure that the sample was salt-free. After concentration to a suitable volume, the 
dialysed sample was run down an fplc Mono-Q anion exchange column, again 
equilibrated with lOmM Tris-HCL pH 8.0 and fractions were eluted using a 0 to 
0.4M NaCl gradient. Fractions were selected for homogeneity of the 68kDa 
component by SDS-PAGE, pooled and run down a fplc Superdex 200 gel filtration 
column equilibrated with the same buffer. Appropriate fractions were pooled and 
concentrated and SDS-PAGE showed the degree of purity of the sample (Fig. 2.1). 
The purification table is shown in Table 2.2.














crude 5.0 131000 26200 1 100
mono-q 1.8 106560 59200 2.26 81
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Table 2.2 Purification of 68kDa M.viridifaciens neuraminidase, using 
















12.56 204979 16320 1 100
mono-q 2.54 143383 56450 3.46 70
superdex 1.49 87016 58400 3.58 42
Fig. 2.1 10 % SDS-PAGE gels displaying the purity of a) 41kDa protein, b) 
68kDa protein.
a) SDS-PAGE of the 41kDa protein after fplc mono-q anion exchange. Lane A 
shows the molecular weight markers. The same purified 41kDa protein sample was 
applied to lanes B, C and D, but the concentration of the sample applied to lane B 
(approximately lO m gm l-1) was twice that of C and D.
A B C  D
b) SDS-PAGE of protein fractions that eluted from the superdex gel filtration 
column (lanes A to E). The first major band in lanes A to E corresponding to the 
purified 68kDa protein is clearly visible. Lane F shows the molecular weight 
markers.
A B C D E
1 0 7 K
7 6 K
5 2 K
3 6  K  
2 7 K  
1 9  K
Crystallization trials
All trials were set up using the hanging drop vapour diffusion method. Protein 
concentration and volume in the drop, type and pH of buffer, molecular weight and 
concentration of the precipitant PEG and volume of the reservoir solution were all 
varied to find the optimum conditions for crystallization.
Crystallization of the 41kDa form of M.viridifaciens neuraminidase
The optimum conditions found for crystallization of the 41kDa form were 
based on those previously reported by Taylor et at. (1992). A variety of conditions 
gave good quality crystals, these being based on 8% PEG 3350 as precipitant at 
pH 5.0 to 5.5. Drop sizes were 6fll, consisting of equal volumes of reservoir 
solution and protein of concentration 12mg/ml. Large crystals were observed, with
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dimensions up to 1.4mm x 0.5mm x 0.5mm (fig. 2.2), after about a week of 
incubation at room temperature.
Fig. 2.2 Typical 41kDa crystals.
Crystallization of the 68kDa form of MMridifaciem  neuraminidase
In comparison with the 41kDa crystals, good quailty 68kDa crystals were more 
difficult to obtain. Initially, small crystals were obtained of dimension 0.23 x 0.23 x 
0.23mm, using 2% PEG as precipitant, pH=5.0, with a protein concentration of 
8mg/ml and total dropsize=8pl. These crystals diffracted weakly to 6A. After an 
exhaustive screening process, including use of the magic 100 incomplete factorial 
matrix (Jancarik & Kim, 1991) which was however unsuccessful, crystals were
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obtained of a different crystal type as judged by subsequent analysis, by 
microseeding followed by macroseeding. All drops contained 0.1M Tris buffer pH
8.4 and 8% PEG 8K as precipitant. The initial drop contained 3p,l of protein at a 
concentration of 12 mg/ml and 3p.l of 8% PEG 8K, 0.1M Tris pH 8.4. A 3|il 
volume of a small crystal suspension obtained from the initial drop were then 
dissolved in lOOfil of the well solution and aspirated violently. 1 pil of this solution 
was then added to 3pl of protein and 3p.l of new well solution. Finally, the larger 
crystals obtained from this trial were washed in successive buffers containing 
increasing concentrations of PEG 8K up to 8% and macroseeded in a solution 
containing 1 jlxI of protein and 3|il of well solution. Crystals up to 0.4 x 0.1 x 
0.1mm were obtained after under a week of incubation at room temperature. 
Diffraction extended to 2.8A from these crystals. However after approximately one 
month of incubation at room temperature, a crystal of superior quality was 
obtained from a hanging drop initially containing 3pl of 4% PEG 8K, 0.1M TRIS 
pH 8.2 and 3|il of protein of concentration 12mg/ml (fig. 2.3). The crystal 
dimensions were 0.2 x 0.5 x 0.5mm. Diffraction extended up to 2.5A at the 
synchrotron from this crystal.
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Fig 2.3 Higher quality 68kDa crystal.
Discussion
The purpose of purification in both cases was to provide protein of a suitably high 
purity to begin crystallization trials. From inspection of the SDS-PAGE gels, it can 
be seen that the 41kDa sample obtained was significantly purer than the 68kDa 
sample. Although it has been well documented that impurity can be a major reason 
behind the failure of proteins to crystallize (Abergel et al., 1991), the purified 
68kDa and 41kDa protein samples were of high enough purity to produce good 
quality crystals. The difficulty in obtaining good quality crystals of the 68kDa form 
of the enzyme could be c.ttributed to impurities in the protein sample and/or ease of 
cleavage of the 68kDa protein to the 41kDa form. In fact, 41kDa crystals were 
repeatedly produced in 68kDa crystallization trials, sometimes in the same hanging
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diop as 68kDa crystals. Affinity purification of sialidases has been reported 
(Suzuki et al., 1993; Milligan et al 1980) and may be a technique that could be 
utilized in the future to improve purification of the 68kDa form of M.viridifaciens 
neuraminidase. Unfortunately, due to time constraints in the project, this method 
could not be developed in the purification reported here.
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Chapter 3
NATIVE DATA COLLECTION 
AND ANALYSIS
Introduction
Once suitable crystals have been obtained, data collection can then begin. All data 
for the 41kDa crystals were obtained in-house on a Siemens Area Detector, whereas 
data for the 68kDa crystals were also collected using a synchrotron source at station 
X31, DESY, Hamburg, Germany on a 18cm MAR image plate. The XDS (Kabsch, 
1988) suite of software was used for subsequent data analysis in all cases, except the 
final 68kDa data set where DENZO (Otwinowski, 1993) was used.
The Area detector
X-rays of wavelength 1.54A are produced by a rotating copper anode X-ray source, 
with a graphite monochromator used to select Cu Ka radiation, typically operated at 
35-40kV, 70-80mA. The detector type used in-house was a Siemens multiwire area 
detector (model:X-100). The detector is mounted on a moveable 20 arm whose axis is 
coincident with the rotation co axis of a 3-circle goniostat. A Motorola 68010 - based
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PCS computer, running an UNIX operating system controls the goniostat and detector 
via the camera controller and position decoding microprocessors. A colour monitor, 
connected to the PCS, enables inspection of data as they are collected. The PCS is 
connected to a Micro VAX computer by an Ethernet link.
A schematic diagram of the area detector is shown in Fig. 3.1. X-ray photons cause 
ionization of xenon gas (at 4 atmospheres) in the detector chamber. The high pressure 
of the gas ensures that ionization events occur just behind the 1mm concave beryllium 
window, inhibiting spot spreading due to parallax. The concave nature of the beryllium 
window also helps to minimize parallax by ensuring the electric field lines are 
approximately parallel to the incident X-ray beams. Electrons produced by the 
ionization events are accelerated towards the anode wires, at approximately 5kV above 
ground, causing secondary ionization events and amplifying the signal. The cathodes 
consist of two parallel planes of wires - one with the wires running vertical and the 
other horizontal, enabling the determination of the position of the ionization events in 
two dimensions. The signals produced by the xenon cations as they reach the cathode
wires are passed to the position decoder which decodes the signals as the (X,
coordinate in the anode planes with an effective resolution of 0.2mm. The data are 
stored asa5 1 2 x 5 1 2  pixel array (each pixel 0.2mm on an edge) in memory and written 
to disk at the end of the exposure. Efficiency of data collection depends on the count 
rate in two ways: (1) the decoder can store a second event that arrives whilst it is 
decoding the first, but loses the third and subsequent events; (2) the occurrence of high 
photon flux causes spots to spread out, reducing the effective resolution of the 
detector. The “% late” parameter reported by the PCS is a direct measure of the first
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effect - it represents the number of events arriving at the PCS whilst the previous one is 
being decoded, as a proportion of the total counts recorded. The “% late” is also a 
monitor of the second effect since it is also a function of photon flux.
Fig. 3.1 Schematic diagram of the area detector. The intensity of the diffracted 
beam is determined from the number of electrons at each wire and the x and y value is 







Face of the Wires
4 0
To eliminate local heterogeneity in the detector response due to irregularities in 
the wire spacing, a correction is performed using a radioactive 55Fe X-ray source. A 
“flood field” correction is recorded with the detector being exposed to the 55Fe X- 
radiation. The counts from each pixel are locally re-binned to give a smooth response 
over the detector surface using the program CORRECT. This correction does not 
compensate for any non-local sensitivity differences in the detector response. The 
correction is applied on-line whilst data are collected and thus recorded frames have 
already been corrected in this manner. An additional image is required before data 
collection - the “brass plate” image is collected using the 55Fe source: a brass shield 
which has holes drilled at precise intervals is placed over the detector face. The 
distribution of the spots in the brass plate image in comparison with their known 
position on the brass plate enables a correction for geometric distortion to be made.
Data are collected as a series of consecutive non-overlapping “frames”, with the 
crystal oscillating about the vertical co axis over a small angular range. Each diffraction 
point is divided into a number of slices in co according to the angular width of a frame 
(Aco), from which the three-dimensional profile of the reflection can be reconstructed. 
The small angular range also increases the signal-to-noise ratio of the reflections. The 
crystal is oscillated about the co axis, rather than simply rotated, to minimize errors due 
to fluctuations in the X-ray beam and because the opening of the shutter and the co axis 
motors are not synchronized.
Each frame is stored as a 512x512 byte array with appropriate header 
information on exposure time etc. Pixels which contain more than 255 counts have their
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true count stored in the header and are flagged as “overflows”. The number of 
overflows on a frame thus depends on the number of diffraction maxima and their 
strength. Frames are transferred from memory directly to the MicroVAX disk.
Data collection in house
Each crystal was drawn into a thin-walled glass capillary tube, with a minimum 
amount of mother liquor from the hanging drop and the tube sealed with beeswax. The 
capillary tube was then mounted on the goniometer head and secured with plasticine. 
The crystal was positioned in the X-ray beam by adjusting the translational sledges 
whilst observing the crystal through a telescope.
The minimum crystal to detector distance in centimetres required to be able to 
resolve individual spots is roughly the length of the largest cell axis (in A) divided by 10 
(G.L. Taylor-personal communication). Initially, the crystal to detector distance should 
be relatively large in order to ensure that individual spots do not overlap. However, 
after determination of the unit cell dimensions from data processing, the distance can be 
reduced so that higher resolution data can be collected. The 20 swing angle in the 
goniometer coordinate system and the crystal to detector distance determine the 
maximum resolution of data that can be achieved.
X
dm“ “  2 s if l0  max
20max 0c tan . i ( L '  
I  D j
dmax = maximum resolution, D=crystal to detector distance, r = radius of detector,
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0C = detector swing, 0max = angle of maximum resolution, X = wavelength of X-ray 
beam.
All data were collected in a series of contiguous, non-overlapping frames, with each 
frame representing an oscillation around co of 0.25°. All data were collected at room 
temperature and reduced using the XDS suite of software (Kabsch, 1988).
XDS data reduction
The XDS data processing program accepts frames of data from the Xentronics area 
detector /  MAR image plate and outputs a list of squared structure factor amplitudes, 
together with information about the completeness of data, quality and optionally 
agreement with a reference data set. The program consists of initialization, reflection 
profile collection and post-processing steps. The specific steps are described below and 
summarized in the flow-diagram (fig. 3.2).
1. XYCORR reads the latest brass plate image and determines the radial distortion, as 
described above, thus making an allowance for the difference between the observed and 
known spot positions. A look-up table is created, which is used for correcting for radial 
distortion in each image.
2. INIT reads the first 30 frames of data and calculates the average background at each 
detector pixel. For a given pixel position, each reading is accepted if it is less than three 
standard deviations above the lowest of the readings. The average of these accepted 
readings is then taken as background, so that strong diffraction spots are not 
erroneously taken as background.
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3. COLSPOT locates the centroids of strong spots which are significantly over 
background, for a given number of images. A list of observed spot and spindle 
positions is produced for autoindexing.
4. IDXREF tries to find the unit cell dimensions of the crystal and its orientation with 
respect to the X-ray beam and detector, by reading the list of spot coordinates and 
spindle positions produced by Colspot. The direct beam position and unit cell 
dimensions are refined.
5. COLPROF collects reflection profiles from all the data frames. Crystal orientation 
and unit cell dimensions are refined every 15 frames, using all reflections collected in 
the previous 15 frames. A 3-dimensional reflection profile is generated, represented in 
the output by a simplified box of 9 x 9 x 9 grid points. A good data set typically has a 
compact reflection profile whose centroid is close to the centre of the box.
6. PROFIT performs profile fitting. Signal and background points are distinguished, 
assuming that weak and strong reflections have the same normalized profile. Reflection 
intensities are estimated by a two pass integration procedure. In the first pass, reference 
profiles are learned as a function of position on the detector and spindle angle within 
the data collection range. In the second pass, intensities are estimated for each 
reflection using the nearest reference profile.
7. CORRECT scales the data to correct for X-ray damage to the crystal and variation 
in detector sensitivity. Correct outputs scaled intensities for reflections and their 
standard deviations.
8. GLOREF performs post refinement of all instrument parameters and unit cell 
parameters using all strong reflections.
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9. XSCALE can scale and merge multiple data sets and can apply a semi-empirical 
absorption correction.
Fig. 3.2 Flow diagram summarizing data analysis using XDS.
Reads the Brass plate image






reads spot.xds for autoindexing
collects all spot 
profiles






XYCORR.TABEL (look up table, to correct for 
radial distortion)
BKGPIX.XDS (initial background) 
MODPIX.XDS (active area of images)














PROFIT.HKL (unsealed integrated intensities)
XDS.HKL
UNIQUE.HKL (scaled hkl reflections) 
MISFITS.HKL
Refined crystal and detector parameters
Scaled data sets (and merged optionally)
Synchrotron data collection
A typical modern synchrotron radiation source consists of a storage ring in which 
charged particles (electrons or positrons) are circulated for long periods of time. These 
particles are accelerated by a linear accelerator and then injected either directly into the
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storage ring where they are accelerated to a desired energy or into a booster storage 
ring where the energy is increased before injection into the storage ring. In the storage 
ring the particles travel through bending magnets that define their path and straight 
sections where the bunch shape is defined by quadrupole or sextupole magnets. The 
intensity of the synchroton radiation is increased by Wigglers, which are a series of 
magnets that cause the particle beam to undergo multiple transverse excursions from 
the normal pathway. As a result, the energy of the radiation is increased and the 
spectrum is shifted to smaller wavelengths. The use of synchrotron radiation as 
opposed to an in-house source gives several distinct advantages:
1. Absorption and radiation damage are reduced, due to the shorter wavelengths of 
synchrotron radiation which can be used.
2. The wavelength of the synchrotron radiation can be tuned, due to the broad 
spectrum that is emitted. Applications that can exploit this are Laue crystallography 
(Pai, 1992), and multiple wavelength anomalous diffraction (MAD) phasing 
(Hendrickson, 1991).
3. Higher resolution data can be collected due to the high intensity of the X-rays. In 
addition, since the radiation is more intense, a data set can be collected to a high degree 
of completeness more quickly.
Data processing was again performed using the XDS suite of software as 
described above, but the final 68kDa data set was reduced using DENZO. DENZO 
performs profile fitting to all the predicted spots on the images collected. The user can 
determine the size of the box, in which the spot and background are integrated. A % 
test is calculated for every reflection, where an overall value of less than 2 indicates
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good data processing. DENZO can also refine all the crystal and instrument parameters 
simultaneously. These include unit cell dimensions, wavelength used, direct beam 
coordinates and crystal to detector distance. SCALE then merges all the processed 




Parameters for data collection were as follows: 
crystal to detector distance = 12cm 
X-ray generator settings = 50kV, 80mA 
exposure time = 120 - 180 seconds/frame 
20 swing angle = 30° 
temperature ~ 21°C
The source of protein for all the 41kDa crystals from which data were collected 
was the culture filtrate.
Diffraction extended to 1.82A from the in-house rotating anode source for native 
crystals of the 41kDa form of the enzyme and a summary of the data collection 
statistics are shown in table 3.1. This data file consisted of five merged data sets, each 
obtained from one crystal of dimension approximately 1.6 mm x 0.6 mm x 0.6 mm. The 
crystals were judged to be of space group P2i2i2i, from observation of systematically 
absent or weak axial reflections.
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The unit cell volume = 337527A3, molecular mass = 41kDa/monomer. So if we 
assume that there is one monomer in the asymmetric unit:
337527
Vm = = 2.03A3/Da which is in the reported range given by Matthews for
41000 x 4
crystals (Matthews, 1968). Since the fractional volume occupied by solvent in the
1.23
crystal = 1--------, the solvent content of the crystal was estimated to be 38.5%.
Vm













- 9.0 5 4 1.3 1.3 3.3
9.0 - 6.0 3762 658 98.5 95.2 4.6
6.0 - 4.0 15999 2148 100.0 98.3 4.7
4.0 - 3.0 30907 4082 99.3 97.4 5.1
3.0 - 2.0 95748 16363 98.3 92.0 6.3
2.0-1 .82 21875 6566 81.1 63.9 9.4
oc-1.82 168,296 29,821 93.4 85.5 5.5
48.14 82.73 84.75 90.0 90.0 90.0
*Ri = 2.2
where Ih is the weighted mean measured intensity of the observations I  hi in which 
the intensities of the symmetry related reflections, which should be the same, are 
compared. Rj, or the merging R factor gives an estimate of their disagreement.
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68kDa Crystals
The native data set was collected for the 68kDa crystals from: 1. In-house 4A 
data set (September 1994) 2. Hamburg synchrotron 2.8A data set (November 1994) 
and 3. Hamburg 2.5A data set (May 1995).
Parameters for data collected in house were as follows: 
crystal to detector distance = 12cm 
X-ray generator settings = 40kV, 100mA 
exposure time = 5 minute s/frame 
20 swing angle = 5° 
temperature * 21°C
The source of protein for all the 68kDa crystals from which data were collected 
was the culture filtrate.
Initially, crystals of the 68kDa form of dimension approximately 0.4mm x 
0.1mm x 0.1mm only diffracted to 4A on the in-house source (table 3.2). However, 
diffraction from crystals of the same size extended to 2.8A at the DESY synchrotron, 
Hamburg, on station X31 at a wavelength of 0.993A (table 3.3). Due to time 
constraints though, only 54° of data were collected in 1° frames from one crystal, with 
exposure times of between 170 and 300 seconds. After merging of the in-house and 
synchrotron data sets with XSCALE , a data set was obtained (table 3.4) with a 
completeness of 57.2% at 3.5A (>1g).
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A larger 68kDa crystal of dimensions 0.5 x 0.4 x 0.2 mm was used at a later date, to 
collect a further Hamburg data set, which was 80.7% complete to 2.5A (>la). Data 
processing statistics are shown in Table 3.5.
After data analysis using XDS, the crystals of the 68kDa enzyme were determined to 
be of space group P2i, as judged by systematic absences of the type OkO: k = 2n.
The unit cell volume = 349650A3, molecular mass = 68kDa/monomer. So if we 
assume that there is one monomer in the asymmetric unit:
349650
68kDa occupies a volume of 349650A3, s o  = 2.57A3/Da which is in the
68 x 2
reported range given by Matthews for crystals. Since the volume occupied by solvent in
1.23
the crystal = 1- , the solvent content of the crystal was estimated to be 52%.
Vm













°o - 10.0 740 361 89.6 87.3 2.7
10.0-6.0 2972 1377 93.5 80.6 6.0
6.0 - 5.5 1068 522 91.7 73.8 8.4
5.5 - 5.0 1172 745 92.5 73.9 7.2
5.0 - 4.5 1301 1084 88.9 70.4 4.3
4.5 - 4.0 1723 1488 76.9 50.9 5.6
- 4.0 8976 5577 87.2 68.9 5.5
cell dimensions a b c a  (3 y
51.13 117.10 60.01 90.0 95.58 90.0
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oo - 10.0 1048 362 89.1 87.4 4.8
10.0 - 6.0 4403 1384 93.2 82.7 8.0
6.0 - 5.0 3562 1273 92.9 79.7 10.0
5.0 - 4.0 5989 2652 85.7 70.0 9.8
4.0 - 3.5 4351 1870 57.2 40.1 12.7
3.5 - 2.8 8443 3501 31.3 18.9 17.7
°° - 2.8 27,796 11,042 55.7 42.3 10.3
cell dimensions a b c a  3 Y
51.03 117.41 60.07 90.00 95.62 90.00
Table 3.4 Merged Hamburg (November 1994) synchrotron and in-house 68kDa 













oo- 10 1,048 362 89.1 87.4 4.8
10-6 4,403 1,384 93.2 82.7 8.0
6-4 .5 6,010 2,357 91.7 78.9 9.2
4.5 - 4.0 3,541 1,568 82.6 64.8 10.9
4^ 0 1 u> Ln 4,351 1,870 57.2 40.1 12.7
9° Lr\ i o 5,475 2,210 34.3 22.9 15.4
oo - 3.0 24,828 9,751 62.4 49.1 9.9
cell dimensions a b c a  3 y
51.03 117.41 60.07 90.00 95.62 90.00
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Table 3.5 Hamburg (May 1995) synchrotron 68kDa native data set processing











4.27 - 3.97 984 80.5 80.2 3.0
3.55 - 3.39 1004 81.6 81.3 3.7
3.15-3.05 1003 81.8 81.8 4.5
2.89 - 2.82 1024 80.8 79.9 5.9
2.69 - 2.64 1026 81.6 80.4 7.7
2.54 - 2.5 974 77.4 71.7 10.4
00-2.5 20083 80.7 80.0 3.7
cell dimensions a b c a  3 y
51.28 117.30 60.24 90.0 96.17 90.0
Discussion
A high quality native data set for the 41kDa form was obtained in-house. 
However, it was necessary to collect data at the synchrotron for the 68kDa crystal. As 
described above, due to time constraints the first synchrotron data set collected from 
the 68kDa crystal contained only 54° degrees of data and this is reflected in the 
completeness of the final merged data set. After the initial difficulty in obtaining higher 
quality crystals, a 2.5A 68kDa data set was finally obtained and this was used for 
solving the 68kDa form by molecular replacement. Cryogenic techniques were also 






For macromolecular structure determination an interpretable electron density map is 
essential, into which the polypeptide backbone of the protein can be built, and the side 
chains inserted. The calculation of such a map requires that both the amplitudes and 
the phases of the diffracted X-rays are known since the electron density equation is 
given by the formula:
1 iothki -2  7ii(hx+ky+lz)
p (x,y,z) = — 2-Fhkl e e
v m
The amplitudes of the diffracted rays can be obtained from the intensities of the 
spots in the diffraction pattern since amplitude (F) is directly proportional to the square 
root of the intensity. However all the phase information is lost in the diffraction 
experiment, since there is no lens capable of focusing the X-rays. This is known as the 
phase problem and is solved indirectly in macromolecular crystallography via either 
isomorphous replacement or molecular replacement. Molecular replacement will be 
discussed in Chapter 6 and in Appendix 2.
The technique of isomorphous replacement was employed in the structure 
elucidation of the 41kDa form of M.viridifaciens neuraminidase. There are generally
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large solvent channels present within protein crystals offering routes along which heavy 
atoms can diffuse, to reach molecules throughout the crystal. In order to obtain a 
suitable derivative the heavy atoms should bind to the same site(s) on every molecule. 
The addition of a sufficiently electron dense heavy atom will produce observable 
changes in the diffraction pattern. The position of the heavy atoms can be located using 
the Patterson method and from the intensities of the native and derivative diffraction 
patterns, the phase problem can be solved (Appendix 2). For centrosymmetric crystals, 
a single heavy atom derivative will be sufficient to unambiguously determine the phase. 
However there is ambiguity in the phases for non-centrosymmetric crystals and this is 
generally overcome by using at least one further derivative. The search for heavy atom 
derivatives is generally by a “trial and error” process and hence can often be a time- 
consuming, arduous task. Hints about possible heavy atom derivatives can be obtained 
from the amino-acid sequence, e.g. binding of mercury compounds to sulphydryl 
groups, but without a detailed knowledge of the crystal structure, it is not possible to 
have a completely rational approach. A derivative may be obtained in one of two ways; 
either by soaking a solution of the heavy atoms into the crystal, or by cocrystallizing in 
the presence of heavy atoms.
Obtaining phases from heavy atom derivatives
The derivative hkl reflection file obtained in the way described in Chapter 3, is merged 
to a unique set of data using a modified version of XSCALE, called XX, which 
preserves the Friedel pair intensities. Figure 4.1 shows the steps employed in obtaining 
Patterson maps to locate the heavy atom positions.
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Fig. 4.1 Flow diagram illustrating the steps involved in generating Pattersons.




















The derivative and native hkl reflection files are converted to lef format using X2L, 
which can then be converted to mtz format with LCF2MTZ for use in the CCP4 suite 
of programs. The mtz file contains structure factor amplitudes and their standard 
deviations and anomalous differences and their standard deviations, if present for the
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derivative, for all reflections of the type hkl. The derivative and native mtz reflection 
files are merged in MTZUTILS and the derivative is scaled to the native using 
LOCAL.
LOCAL scales the combined data sets in two distinct stages. Firstly, an overall 
scaling is performed which uses an anisotropic temperature factor followed by local 
scaling. Thus the data are reasonably well scaled before local scaling is employed. 
LOCAL can also scale Friedel pair differences, arising from anomalous scattering by 
heavy atoms in the derivative. The scaled mtz file is read into FIT  which outputs an 
isomorphous difference Patterson map. The Patterson map is generated by the 
synthesis:
1 y  2 -27ti(hu+kv+lw)
P  (u,v,w) = —  2L, (Fph-Fp) e  
V  hkl
FFT can also generate the anomalous difference Patterson map, calculated with 
respect to disparity between the Bijovet pairs. The Patterson synthesis here is the same
as for the above, except with coefficients (Fph(+) - FPH(-))2.
PLUTO plots sections of the Patterson maps. In the case of the 41kDa form, 
the space group was P2i2i2i and Harker sections lie at u=l/2, v=l/2, w=l/2.
The isomorphous difference Patterson or anomalous difference Patterson map 
produced by the FFT is then read into VECSUM, which deconvolves the Patterson 
function and produces a map of the possible heavy atom sites in the structure. Once an 
initial possible heavy atom site has been located, its coordinates are put back into 
VECSUM and further sites searched for. All genuine peaks were manually located on 
the Harker sections. A summary of the steps involved in location and refinement of 
heavy atom sites in order to obtain phase information is shown in Fig. 4.2.
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The merged native and derivative (combined.mtz) reflection file from 
MTZUTILS is read by FHSCAL which scales the data using Kraut’s formula (Kraut et 
al., 1962) and outputs a scale factor (Vf). This is used in FFT to produce a correctly 
scaled isomorphous difference Patterson. VECREF then refines the putative heavy 
atom positions, reading the scaled isomorphous difference Patterson map and the 
putative heavy atom site coordinates. MLPHARE refines the heavy atom positions and 
calculates phases, giving a variety of statistics regarding the quality of the phase 
information.
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The Search for successful derivatives
Crystals were soaked in solutions of Gold, Platinum, Iodine, Thorium, Cadmium 
and Lanthanum. Table 4.1 lists the unit cells for the derivatised crystals.
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Table 4.1 Summary of some of the unit cells of the derivatised crystals.
a (A) b (A) c(A) cc=p=y
(°)
native 48.14 82.73 84.75 90
K2PtCl6 48.00 82.97 85.35 90
Th(N03)2 48.11 83.14 85.06 90
NaAuCfl 48.05 82.95 85.23 90
CdCl2 48.02 83.10 85.01 90
k i3 48.11 82.92 85.12 90
La(CH3COO)3 48.15 83.16 85.07 90
a) Unsuccessful derivatives
Heavy atom soaks which resulted in either non-isomorphism or a native crystal 
are listed briefly here. All possible peaks were verified in VECREF, but the derivative 
was not pursued when the occupancies refined to zero and gave poor correlations and 
residuals.
1. K2PtC l6 - soaked for 2 days at a concentration of 2mM. Possible sites
from VECSUM gave poor correlations and residuals in VECREF. The crystal was 
therefore deemed to be native.
2. NaAuCU - soaked for 2days and for 1 day at a concentration of
2m M . Both conditions resulted in poor correlations and residuals in VECREF. Both 
crystals were therefore not derivatives.
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3. Th(N03 )2  ■ soaked for 1.5 hours at a concentration of 2mM. The data
set for this soak resulted in a fractional intensity difference of only 5.3%. In addition, 
the isomorphous difference Pattersons showed no peaks.
4. K I3 - soaked for 1.5 hours at a concentration of 5mM. The Pattersons
obtained from this data set showed no obvious peaks. The map was “smeared out” 
indicating possible non-isomorphism.
b) Successful derivatives
Data collection statistics for the derivatives which gave useful phase 
information are summarised in Table 4.2. Refinement statistics for the heavy atom sites 
are summarised in Table 4.3. The grid used in VECSUM was 48 44 44 for a resolution 
of 3.0A.
1. C dC h - soaked for 2 days at a concentration of 2mM. Two potential
sites from VECSUM with grid coordinates 26 8 25 and 2 35 19 were found. After 
refinement in VECREF one major and one minor site was identified respectively. The 
cross vector peak corresponding to the two sites was also identified.
2. La(CH 3COO)3 - soaked for 3 days at a concentration of 2mM. One 
potential heavy atom site was identified from VECSUM with grid coordinates 21 17 
13 and refinement in VECREF gave reasonable correlations and residuals indicating 
one major heavy atom site.
3. K I3 - soaked for 10 days at a concentration of 0.2mM.
(as for the Lanthanum derivative, with VECSUM grid coordinates 18 19 35)
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4. T h(N 03)2 - soaked for 2 days at a concentration of 2m M . One major 
peak was identified in VECSUM with grid coordinates 24 18 15 and subsequent 
refinement in VECREF gave reasonable residuals and correlations as well as a high 
occupancy, reflecting the peak height in the isomorphous difference Patterson (7a in 
w=l/2 Harker section).
Table 4.2 Data collection statistics for the heavy atom derivatives.
derivative Th(N03)2 CdCl2 k i3 La(ac)3
No. of observations 24330 24240 24577 24521
No.of unique reflections 6589 6327 6814 6665
Completeness (%) 93.8 90.8 98.7 92.0
Resolution (A) 3.0 3.0 3.0 3.0
Ria (%) 6.9 6.9 10.4 10.5
Table 4.3 Summary of statistics for the heavy atom sites, together with the 






















I Cdl 0.54, 0.09, 0.28 0.431 0.862 1.35 8.0
Cd 2 0.197 0.04, 0.40, 0.20 0.960 0.187 0.22 1.0 0.24 0.45 0.31
I 0.148 0.36, 0.22, 0.40 0.611 0.666 0.33 3.0 0.06 0.23 0.43
La 0.260 0.46, 0.20, 0.15 0.560 0.681 0.38 5.0 0.02 0.51 0.38
Hi 0.473 0.50, 0.20, 0.17 0.656 0.707 3.20 5.0 0.06 0.49 0.37
* max peak height is defined here by the maximum sigma level on the Harker 
section u=l/2
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The scaling statistics for the derivatives of Cadmium, Thorium, Iodine and 
Lanthanum are illustrated graphically in Fig. 4.3.
The isomorphous difference Pattersons for the section u= l/2  are illustrated in Fig. 
4.4, for the successful Lanthanum, Cadmium, Thorium and Iodine derivatives. The 
maps are all contoured at l o  and peaks due to heavy atom sites are labelled as is the 
cross vector peak for the Cadmium derivative.
Fig. 4.3 Scaling statistics for the successful derivatives. Rms fractional intensity 
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Fig. 4.4 u=l/2 Harker sections at 3A for the successful derivatives. For each 
section A = peak corresponding to the heavy atom site. For the Cadmium Harker 
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Anomalous data
Anomalous difference Patterson maps were also calculated, but there were no 
significant peaks on the Harker sections u=l/2, v=l/2 and w=l/2 due to anomalous 
scattering. In addition, minor peaks on the anomalous Harker sections did not 
correspond to heavy atom peaks found on the isomorphous difference Pattersons. 
Hence, anomalous data were not used in future phase calculations.
Obtaining initial phase estimates
All phase estimates were calculated using MLPHARE. The Lanthanum 
derivative gave the first set of phases and then as more derivatives were found, their 
phases were calculated relative to those of the Lanthanum’s. When a peak from 
VECSUM due to the presence of a heavy atom site is chosen, the origin and hand is 
arbitrarily fixed and there is only a 1 in eight chance that the peak due to a second 
heavy atom derivative will have the same origin. The first run of VECSUM shows all 
potential heavy atom sites, with respect to all origins and both hands. The Cadmium 
derivative gave two sites and so one Cadmium site was chosen and fed back into 
VECSUM. The origin and the hand was thus fixed and the second Cadmium site found 
was automatically on the same hand and origin as the first site.
Cross phase difference Fouriers with coefficients p (x, y, z) = ^  FOM (Fnew
hkl
deriv-  F0)e lPHIB were calculated for all the derivatives. Initially, PHIB corresponded to 
tire best phases obtained from MLPHARE for the Lanthanum derivative, FOM 
corresponded to the figure of merits for the Lanthanum derivative and Fnew deriv was
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the structure factor amplitude for the Iodine derivative, the second useful derivative 
found. When the next derivative was to be cross phased, PHIB corresponded to the 
best combined phases from the Lanthanum and the Iodine derivative, FOM 
corresponded to the figure of merit for the combined Lanthanum and Iodine derivative 
phases and Fnew deriv corresponded to that next derivative. Cross phase difference 
Fouriers were repeated in this fashion for the other derivatives that became available. 
Hence all heavy atom sites were put on the same hand and same origin as the 
Lanthanum’s. Although the phases from the Thorium derivative were initially included, 
it was found that the overall phasing statistics were not significantly improved and 
therefore the Thorium derivative was omitted from the final phase calculations.
It was found that the phasing powers of the derivatives were good at low 
resolution, but that as the resolution limit was extended the phasing powers of the 
derivatives dropped off sharply. For example, at 6A the Lanthanum derivative had a 
centric phasing power of 0.9 and an acentric phasing power of 1.5, whereas at 3.0A 
the phasing powers were 0.2 for centric and acentric reflections. However, it was
o
decided that since the resolution of all the derivatives extended to 3.0A, to calculate 
phases in MLPHARE to 3.0A. Table 4.4 gives the phasing statistics for all the 
derivatives after combination in MLPHARE. Fig. 4.5 illustrates how the phasing 
powers of the derivatives varied with resolution, after combination in MLPHARE. The 
mean overall FOM is also given as a function of resolution.
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Table 4.4 Phasing statistics for the derivatives of Cadmium, Iodine and 
Lanthanum at 3.0A; after combination in MLPHARE.
derivative CdCL k i3 La(ac)3
Heavy atom sites C,D B A
Phasing
power (centric, acentric) 
to 3.0A
0.6, 0.8 0.3, 0.4 0.5, 0.7
Cullis R (centric, 
acentric) to 3.0A
0.74, 0.42 0.93, 0.50 0.86, 0.62
Lack of closure (centric, 
acentric)
133.3, 106.0 109.0, 92.8 190.7, 118.8
Isomorphous difference 
(centric, acentric)
179.1, 126.4 117.4, 96.2 221.7, 133.5
Total no. of reflections 5354 6091 6304
Overall Figure of Merit acentric: 0.37 (5177 reflections), centric: 0.54 (1022 
reflections)
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Fig. 4.5 Phasing power vs. resolution for the derivatives of Iodine, Cadmium and 
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Definition of terms used
1ar»lr n f  r*lncnrp - I
, . _ ^  *** r  ^  _ lack of closurephasing power = Rms |  ------------------- f Cullis R =
lack of closure J  isomorphous difference
9  0 .5
V I  /  IfH  \Lack of closure = E *  Ifph ± Fp I - fH I Rms FH = *1 --------------J
/ (  E l l  F ph ±  F p I — fH I )  *1 
Rms Lack of closure = |    j
T , V  11 nat — I deriv I
Isomorphous difference = Za ----- -------------
Residual = The weighted residual between observed and calculated Pattersons. The 
optimal value is zero.
Correlation = The weighted linear correlation between observed and calculated 
Pattersons. The range is 1.0 to -1.0, where 1.0 is optimal.
Mean figure of merit = mean cos(estimated phase error). The range is 0.0 to 1.0, 
where 1.0 is optimal.
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Chapter 5
BUILDING AND REFINING 
THE 41kDa MODEL
Introduction
Initial phase estimates obtained from the heavy atom derivatives and structure 
factor amplitudes provided by the native data set now allowed the generation of an 
electron density map into which the model could be built. In order to generate the 
optimum initial electron density map, several techniques were implemented, which will 
be discussed below. Since the initial phase estimates will be poor due to errors such as 
lack of closure (Appendix 2), obtaining the best map possible is often a time consuming 
process. Errors introduced into the model at this stage as a result of incorrect tracing of 
the polypeptide backbone may be difficult to correct later on and so the model building 
process should be a cautious one.
The initial 3.0A phases derived from the heavy atom derivatives were extended 
up to 2.5A  using solvent flattening, histogram matching and Sayre’s equation in the 
program SQUASH (Cowtan & Main, 1993). However, the phase extended map 
produced by SQUASH did not have significant improvements over the original map 
calculated using the heavy atom phases (MIR map). In addition, phase extended maps 
generated using SQUASH in later stages of the refinement did not show significant
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improvements over the corresponding unextended maps. The generation of a 3.0A 
solvent flattened map, using the WANG algorithm (Wang, 1985), improved the density 
in certain core regions of the map, aiding map interpretation.
There are 4 distinct stages in the process of model building:
1. Defining the molecular envelope.
2. Generating a skeletal representation of the electron density; illustrating the path of 
the C a chain.
3. Fitting the C a positions to the electron density.
4. Insertion of the amino acid sequence into the electron density.
Interpreting the overall fold
To date, all of the neuraminidase structures known have the same overall fold. 
In spite of a relatively low sequence identity of 26.9% between V.cholerae and
5.typhimurium (Crennell et al., 1994) neuraminidase, the neuraminidase domains have 
a very similar overall fold. It was therefore likely that the structure of the 41kDa
M.viridifaciens neuraminidase would strongly resemble that of the neuraminidase from 
S.typhimurium, considering also that both were in the same class of small molecular 
weight neuraminidases.
All map interpretation and model building was carried out using the program 
‘O’ (Jones et al., 1991) on an Evans and Sutherland ESV10/33. The structure of the 
S.typhimurium neuraminidase was manually fitted onto the MIR electron density map. 
A 3A difference Fourier map was calculated from inhibitor (DANA) complex data (this 
was later extended to 2A). The asymmetric shape of the inhibitor was evident and this
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aided the positioning of the homologous S.typhimurium neuraminidase-inhibitor 
complex model onto the MIR map. Rigid body fitting of the structure was also 
performed, but did not improve the fit to the density. A skeletonized representation of 
the electron density map was generated using the program BONES and displayed using 
‘0 ’(0_bones)(Jones et al., 1991). The BONES skeleton is classified into probable main 
chain, possible main chain and side chain, based on length and connectivity of the 
fragment. The C a backbone of S.typhimurium appeared to follow the connectivity 
suggested by the BONES extremely well and the BONES were edited, starting at the 
N-terminus, in order to produce a continuous chain at tire level of probable main chain 
using the b o n es_ b reak  and bones_make commands in ‘O’. Deviations between the path 
of S.typhimurium s Ca  chain and the path predicted by the BONES possible main chain 
were most apparent in the loops. It was also made more difficult to determine the 
connectivity in some, of the surface loops since the solvent flattened map was cut off 
and the MIR map appeared disordered in places.
Assigning the Ccx positions
The next step in the model building was to assign the C a positions to the 
electron density. Several conserved features in tire structure of S.typhimurium 
neuraminidase aided this assignment by acting as “markers”. These features consisted 
of:
1. FRIP motif in the salmonella enzyme. The FRIP motif at the N-terminus of the 
S.typhimurium. enzyme is replaced by a YRIP motif in the 41kDa M.viridifaciens
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neuraminidase. The arginine and the proline are completely conserved across all the 
neuraminidases, the arginine being a conserved active site residue.
2. Asp-boxes. Asp-boxes are known to be located at spatially equivalent positions 
along the polypeptide chain.
3. Conserved active site residues. These are completely conserved between the
S.typhimurium. and 41kDa M.viridifaciens neuraminidases.
The amino acids in the M.viridifaciens sequence which corresponded to these 
“marker” residues were inserted first and then the intervening residues added. This was 
performed using the bones_move command to move bones atoms to more sensible 
locations if required and the bones_pick_Ca command to actually convert the bones 
atom to the C a of the appropriate amino acid.
Completing the model
The main chain conformation was automatically generated using 
lego_auto_mainchain and then the side chains were automatically inserted using 
lego_auto_sidechain. This process takes no account of the density, but fits portions of 
structure based on O’s database of well refined structures to a high resolution. Hence it 
was then necessary to go through the whole of the structure, residue by residue, using 
the move commands (move_zone, move_fragment and move_atom) in order to place 
the C a atoms and side chains in the best positions corresponding to the density, and 
using the Lego_mainchain and Lego_sidechain commands to obtain the most 
appropriate rotamers. Now that a complete model had been obtained, the iterative 
process of refinement could be initiated.
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Refinement of the 41kDa model
X-PLOR version 3.1 (Brunger, 1988) was used in the refinement of the 41kDa 
M.viridifaciens neuraminidase. A summary of the stages in the refinement of the 41kDa 
form of M.viridifaciens is shown in table 5.1. The theory behind the process of 
refinement is discussed in Appendix 2, together with a more detailed explanation behind 
tire X-PLOR method of refinement.
Initially in the refinement procedure, all the B-factors were set to a value of 
20A 2. Then as the refinement progressed, overall B-factor refinement was performed, 
with the B-factors grouped in order to reduce the parameter/observation ratio. Two 
groups were selected, one consisting of the polypeptide backbone atoms and one 
consisting of the side chain atoms. Individual B-factors were refined in the latter stages 
of the refinement.
Round 1 of refinement
The initial model for the 41kDa form of M.viridifaciens neuraminidase was 
refined in X-PLOR at a resolution of 2.5A. The R-factor dropped from 59.7% to 
44.1% after PREPSTAGE and decreased further to 38.4% after SLOWCOOL. This 
gave some credence to the model, especially since the model was at the earliest stage of 
refinement.
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Round 2 of refinement
It was decided to approach the refinement tentatively, since the quality of the 
phasing statistics dramatically worsened at a resolution greater than 3A. Structure 
factors for the latest model were generated using SFALL (CCP4 suite of programs) 
and phases from the model and the heavy atom derivatives were combined using the 
“COMBINE” option in SIGMAA (CCP4 suite of programs). This option combines 
isomorphous phases, which are input as Hendrickson-Lattman coefficients ABCD, with 
calculated phases for the partial structure and outputs the combined phases and Fourier 
coefficients 2 m F0- D Fc, where m is the figure of merit, and D is a factor dependent on 
the coordinate errors (Luzzati, 1952). Where regions of the initial 3.0A MIR and 
WANG maps were ambiguous or poor, these were omitted from the model and the 
corresponding partial map generated. As the maps gradually improved, more of the 
complete model was incorporated in the refinement. The R-factor for the complete 
model dropped from 38.1% to 36.3% in PREPSTAGE and then decreased to 31.8% 
after SLOWCOOL. A further 5 cycles of refinement of the complete model in X- 
PLOR, with concomitant manual rebuilding, resulted in a final R-factor of 27.7% after 
SLOWCOOL. Refinement of grouped B-factors was then implemented and the R- 
factor dropped to 25.1%.
Rounds 3 and 4 of refinement
A new combined map at an extended resolution of 2.5A was generated. 
However the map was poorer than expected and it was postulated that at this stage of
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the refinement, including the inaccurate phases derived from the heavy atom derivatives 
had the effect of preventing significant enhancement of the map. Therefore a 2F0-FC 
map was generated, without combining phases from the heavy atom derivatives. Those 
residues which lay outside the most favoured regions of the Ramachandran plot 
(Ramachandran & Sasisekharan, 1968) were examined closely and after manual 
rebuilding with refinement in X-PLOR, the R-factor after SLOWCOOL was 26.4%. 
Grouped B-factor refinement reduced the R-factor to 24.6%.
Round 4 of refinement was implemented as a second cycle of round 3, 
examining the Ramachandran outliers remaining. In round 4 however, the resolution 
was extended to 1.8A and SLOWCOOL was followed by refinement of individual B- 
factors. Individual B-factor refinement gave an R-factor of 27.4%.
Round 5 of refinement
In order to reduce the bias from the model, OMIT maps were calculated in 
X-PLOR , in an 8A sphere around those residues which were still present in 
unfavourable regions of the Ramachandran plot. OMIT maps exclude phase 
information for a specified region of the model in the generation of the new map. 
Examination of the resultant OMIT map may reveal mistakes made in previous map 
interpretations. After subsequent reinterpretation of the positions of the Ramachandran 
outliers, the model refined to 26.4% after individual B-factor refinement (27.2% after 
SLOWCOOL).
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Round 6 of refinement
Although the omit maps revealed subtle changes that could be made in the 
orientation and position of some of the side chains, there were no clear indications as to 
whether any grosser changes were necessary. In addition, 8 residues still had phi, psi 
angles in generously allowed regions of the Ramachandran plot and 2 residues had phi; 
psi angles in disallowed regions of the Ramachandran plot. Therefore simulated 
annealing omit maps were generated, omitting a sphere of 8A, or a stretch of residues 
around these remaining Ramachandran outliers. Simulated annealing omit maps differ 
from conventional omit maps in that a specific region of the model is omitted from the 
SLOWCOOL refinement. The refined model from SLOWCOOL is then used to 
generated the OMIT map. The simulated annealing omit maps revealed that in several 
places some of the amino acids were “bunched up” resulting in residues further along 
the polypeptide chain being one or two residues backwards or forwards from their 
correct position. After manual rebuilding of these residues followed by refinement in 
SLOWCOOL, the R-factor decreased to 26.3% and 25.8% after individual B-factor 
refinement.
Round 7 of refinement
The Ramachandran plot had now improved, and there were only 4 residues in 
generously allowed regions and one residue in the disallowed region. In order to 
identify whether it was necessary to shift any further residues backwards/forwards,
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conventional omit maps were generated, omitting 10% of the total number of amino 
acid residues at a time (about 35 amino acids) over the whole structure. However these 
maps did not significantly aid interpretation and so a simulated annealing omit map was 
generated over the stretch of residues 275-291. This region had produced a poor 3D- 
1D score (Luthy et al., 1992) (see quality of the final model) and residues Phe 270 and 
Glu 277 were in generously allowed and disallowed regions of the Ramachandran plot 
respectively. The simulated annealing omit map revealed that following the catalytic 
residue Arg 276, the residues needed shifting one residue further forwards, up to Ser 
289; the start of the fourth Asp-box. The resulting model refined to an R-factor of 
25.0% in SLOWCOOL and had an R-factor of 24.4% after individual B-factor 
refinement.
Round 8 of refinement
Two simulated annealing omit maps, omitting residues 210-225 and 225-248 
clearly showed the need to shift residues His 217 to Ala 231 one further back along the 
polypeptide chain. This explained the presence of His 217 in the generously allowed 
region of the Ramachandran plot. The R-factor for the resulting model decreased by 
1% to 23.4% after B-factor refinement. The resulting model now had only 4 residues in 
the generously allowed region of the Ramachandran plot and there were no residues in 
the disallowed region.
As a final check to ensure that there were no further improvements that could 
be made by manual manipulation of the structure, simulated annealing omit maps were
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generated across the whole structure, omitting 10% (35 residues) of the total number 
of residues at a time. The maps did not reveal any improvements that could be made.
Round 9 of refinement
Inspection of the 2F0-FC map generated using the calculated structure factors 
from the most recent model revealed numerous isolated regions of density, of a high 
sigma level. Water molecules were manually placed in suitable regions of density using 
the water_init and water_add commands in ‘O ’ if they met two criteria:
a) The water molecule could make at least one hydrogen bond to a protein nitrogen 
atom or carbonyl oxygen atom, or another water molecule’s oxygen atom.
b) There were no stereochemical clashes between the inserted water molecules and 
protein atoms.
In total, 151 water molecules were modelled into the 2F0-FC map and the 
resulting model including the water molecules was refined in X-PLOR. The R-factor 
after individual B-factor refinement was 17.9%. A new 2F0-FC map was calculated and 
the water molecules were meticulously checked, to establish whether the above criteria 
were still met. Additional water molecules were added where necessary. This model 
refined to give an R-factor of 17.3% after individual B-factor refinement. Finally 
CONTACT (CCP4 suite of programs) determined if any water molecules were making 
stereochemical clashes with the protein atoms or neighbouring water molecules and if 
any water molecules had zero hydrogen bonds. After three water molecules had been 
rejected using the results of CONTACT, the model contained a total of 270 water 
molecules.
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Table 5.1 Stages in refinement of the 41kDa form of M viridifaciens neuraminidase. 
All refinement was performed with a 2a  cut-off in the reflection file, except in the final 
cycle of refinement, where a Oa cut-off was used.
refinement
round
R-factor (%) resolution (A) temperature 
factor refinement
1 38.4 2.5 none
2 25.1 3.0 b-group
3 24.6 2.5 b-group
4 27.4 1.82 b-individual
5 26.4 1.82 b-individual
6 25.8 1.82 b-individual
7 24.4 1.82 b-individual
8 23.4 1.82 b-individual
9 17.3 1.82 b-individual
Quality of the final model
The structure of the 41kDa form of M.viridifaciens neuraminidase has been 
determined to a resolution of 1.82A and the crystallographic R-factor for all reflections 
between 20 and 1.82A is 17.3%. The final structure consists of residues 47 to 404 and 
270 water molecules have been included in the solvent model for the refined structure. 
Table 5.2 summarizes the refinement statistics for the final model.
Several methods were used to assess the quality of the refined model. Fig. 5.1 
shows how the refined 41kDa model correlates with the 2Fo-Fc electron density map. 
The 3D-ID score (Luthy et aL, 1992) which gives a score for the biochemical sense of 
each amino acid side chain of the structure, was greater than zero for all regions of the 
structure (lowest score was 0.15 for residues 309 Pro and 310 Thr in a surface loop), 
indicating that all amino acid side chains were in favourable environments (fig. 5.2).
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Table 5.2 Refinement statistics for the final model of the 41kDa form of 
M . viridifaciens neur a mini da se.
number of non-hydrogen protein atoms 2701
number of water molecules 270
resolution range 6.0-1.82A
number of reflections 28,814
R-factor for all data 17.3%
rms deviation in :
bond lengths 0.016A
bond angles 2.57°
Average temperature factors: 
main chain 11.56A2
side chain 15.10 A2
Fig. 5.1 A typical region of the refined 41kDa model superimposed on the 1.82A 
2Fo-Fc electron density map. The map is contoured at la .
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Fig. 5.2 T he 3D- ID score for the final refined 41kDa model.
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Luzatti plots (Luzatti, 1952) are useful in that they estimate mean coordinate
error for a given structure. Fig. 5.3 shows a Luzatti Plot for the refined structure for
9_____________________ _
data between 6 and 1.82A with a 2c cut-off. The plot shows R-factor versus
resolution superimposed on theoretical curves that consider all discrepancies to be
due to coordinate error. From this graph, the mean positional error is estimated to be
between 0.15A and 0.20A  for the refined native model.
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Fig. 5.3 Luzatti plot for the refined model. The bold line gives the observed R- 
Factor. The broken lines represent the theoretical values associated with a given 
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Procheck (Moms et al., 1992) assesses the quality of the model by a variety of 
different methods. Procheck outputs a Ramachandran plot for the model and highlights 
those residues that possess <|>, (p angles in outlying regions. As can be seen from fig. 5.4, 
there are no residues in the disallowed regions of the Ramachandran plot and only four 
in generously allowed regions, leaving 98.7% of residues in most favoured and 
generously allowed regions.
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Fig. 5.4 The Ramachandran plot for the refined model of 41kDa M.viridifaciens
neuraminidase.
Phi (d egrees)  
P lo t  s ta t is t ic s
Residues in m o st favoured regions [A .B.L] 256 88.3%
R esidues in  additional allow ed regions [a.b.l.p] 30 10.3%
R esidues in generously allow ed regions [~ a .-b .~ l,—p] 4 1.4%
R esidues in disallow ed regions 0 0.0%
N um ber o f  non-glycine and non-proline residues 290 100.0%
N um ber o f  end-residues (excl. G ly and Pro) 1
N um ber o f  glycine residues (shown as triangles) 43
N um ber o f  proline residues 24
Total num ber o f residues 358
B ased  on an  ana lysis  o f  1 18 s tru c tu re s  o f  re so lu tio n  o f  a t least 2.0  A n g stro m s 
and  R -fa c to r no  g re a ter th an  2 0 % . a  g ood  q u ality  m o d e l w o u ld  b e  ex p e c ted  
to  h av e  over 9 0 %  in th e  m ost fav o u red  reg ions.
Procheck also provides information on various main chain and side chain 
parameters and these are summarized in fig. 5.5. The average temperature factors for 
main chain and side chain atoms were 11.56A2 and 15.10A2 respectively and a plot of
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temperature factor vs. residue is given in fig. 5.6. The rms deviation in bond lengths 
and angles from ideality were 0.016A and 2.57° respectively following the final cycle of 
refinement.
Heavy atom binding sites
The location of the heavy atom sites was investigated with respect to the refined 
structure (fig. 5.7). The Lanthanum heavy atom compound bound to Glu 48 and Glu 
62. Glu 62 was from a separate symmetry related molecule. The Lanthanum binding 
site was also the binding site for the second Cadmium atom. The first binding site for 
the Cadmium compound was Asp 304 and Asp 302. The binding site for the Iodine 
atom compound was Tyr 240.
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Fig. 5.5 (a) Main chain and (b) side chain parameters for the refined 41kDa 
M.viridifaciens neuraminidase.
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Comparison values No. of 
No. of Parameter Typical Band band widths 
Stereochemical parameter data pts value value width from mean
a. Chi-1 gauche minus st dev 61 11.8 16.3 6.5 -0.7 Inside
b. Chi-1 nans st dev 79 18.0 17.5 5.3 0.1 Inside
c. Chi-1 gauche, plus st dev 118 16.0 16.0 4.9 0.0 Inside
d. Chi-1 pooled st dev 258 15.7 16.6 4.8 -0.2 Inside
e. Chi-2 trans st dev 66 14.7 19.3 5.0 -0.9 Inside
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Fig. 5.6 Temperature factor vs. residue for the refined 4IkD a M.viridifaciens 
neuraminidase.
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Fig. 5.7 Location of heavy atom sites in the 41kDa form of M viridifaciens 
neuraminidase. Cdl is the first Cadmium heavy atom site, Cd2 the second Cadmium 





The method of deriving starting phases in order to solve the electron 
density equation (Chapter 4) using a known structure, is molecular replacement. If 
the structure of a new protein is suspected to be similar to that of a known 
structure (e.g. from sequence similarity), then the known structure may be used as 
a phasing model for determining the structure of the new structure. The phases of 
atomic structure factors and hence of molecular structure factors, depend on the 
location of atoms in the unit cell. So in order to use a known protein as a phasing 
model, it is necessary to perform a six dimensional search in the unit cell of the 
protein with unknown structure, in order to determine the orientation and position 
of the known structure that would give phases most like those of the new protein. 
In order to save on computing time, the search is split into two parts; orientation 
(the rotation function) and the position of the search model (translation function). 
The theory behind the use of the rotation and translation functions in molecular 
replacement will be discussed in Appendix 2.
The Strategy
Since the stricture of the 41kDa form of M.viridifaciens neuraminidase 
was known, a potentially high quality search model existed for solution of the
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68kDa form by molecular replacem ent Initially, the only data set available for the 
68kDa crystals was 93.5% complete (>1g) to 6A and hence the rotation and 
translation functions were performed with a high resolution limit of 6A. The 
molecular replacement package AMoRE (Navaza, 1992) was used for all 
calculations.
AMoRE
The molecular replacement package AMoRE generates structure factors 
for the model and enables the search of a large number of rotation function peaks, 
as well as the calculation of the corresponding translation functions. AMoRE also 
applies rigid body refinement to the solutions. The search for a molecular 
replacement solution in AMoRE consists of a distinct number of stages, which are 
summarised in fig. 6.1. The first step, SORTING, consists of packing and sorting 
the Fobs for all reflections of the type hkl obtained from the data set for the target 
(unknown) structure. SORTING outputs a packed file of hkl Fobs and SIGFobs in 
the P I asymmetric unit. In the second step, TABLING places the search model in a 
small box and rotates the model coordinates such that the principal axes of inertia 
of the model are parallel to the box axes and translates the coordinates so that the 
centre of mass is at the origin. This ensures an optimum placement of the model in 
order to begin a rotation search. TABLING outputs the new model coordinates 
and prepares a table of continuous Fourier coefficients from the coordinate model. 
The rotation function is carried out in ROTING (Crowther, 1972; Navaza, 1987). 
Firstly, ROTING calculates structure factors for the model in a suitable cell, using 
the Fourier coefficients obtained from TABLING and outputs a set of packed
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structure factors, in the same format as the output from SORTING. ROTING then 
calculates spherical harmonics for both the crystal and the model, which are 
required for calculation of the rotation function. Any promising rotation function 
output solutions can then be put into the TRAING stage of AMoRE. TRAING 
calculates the translation function for a given rotation function output solution, 
using the Crowther and Blow overlap function method (Crowther & Blow, 1967). 
Fast rigid body refinement of any likely rotation and translation peaks can then be 
carried out in FITING, (Castellano et al., 1992). If molecular replacement has been 
successful, then the refined rotation and translation matrix produced by FITING, 
which takes into account the rotation and translation of the search model in 
TABLING, can be applied to the original search model.
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Fig. 6.1 Flow chart summarising the stages involved in molecular replacement
using AMoRE.
x y z coordinates of 
H K L F obs model
optimum model coordinates 
table of Fourier coefficients










rotation and translation 
parameters to apply to 
initial model
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A Molecular replacement solution for the 68kDa form of
M.viridifaciens neuraminidase using AMoRE
A single set of parameters was used in AMoRE, since a molecular 
replacement solution was obtained immediately. The resolution limits of the data 
used for the target structure were between 100 and 6A. Structure factors were 
generated to 4A in TABLING, the Shannon rate for sampling the coordinate map 
was 2 and the scalefactor which determines how finely the model structure samples 
reciprocal space was 4. The sphere radius used in ROTING, within which 
interesting intermolecular vectors should lie, was between Rmin = 0 and Rmax 
(Patterson cut off radii) = 20A. Navaza suggests that this radius of integration 
should not be greater than the maximal distance from the centre of mass, 31.46A 
as calculated by TABLING. The resolution range over which the cross rotation 
function was performed, was between 12 and 6A. A list of the top ten rotation 
function peaks are listed in Table 6.1.
Table 6.1 The top ten rotation function peaks obtained in AMoRE. Symmetry 
related peaks are omitted for clarity ( la  = 8.1).
a 3 y Correlation Coefficient
261.28 100.13 159.18 32.4
98.50 25.00 33.21 29.8
299.74 51.11 10.10 29.5
128.69 87.09 189.36 28.7
150.39 53.74 322.67 28.3
107.04 115.56 53.93 28.1
185.60 87.84 196.98 27.9
104.09 95.16 268.00 27.4
8.84 40.91 137.04 26.5
98.32 103.83 227.65 25.4
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The peak with the highest correlation coefficient and lowest R-factor is 
generally the correct solution. This peak had an AMoRE correlation coefficient of 
32.4 (4.0a), the next highest peak having a correlation coefficient of 29.8 (3.7a).
The rotation function peaks were edited to remove the symmetry related 
peaks and put into TRAING, in order to find the corresponding translation 
function peaks. The translation function search was again performed with 
resolution limits between 12 and 6A, and a Shannon rate of 2. The top ten best 
translation function peaks obtained, corresponding to the above rotation function 
peaks are listed in table 6.2 below. Note that since translations along the b axis are 
arbitrary in space group P2i, all b translations are zero.
Table 6.2 The top ten rotation and corresponding best translation function peaks 
obtained in AMoRE. Symmetry related peaks are again omitted for clarity.
a P Y a b c correlation
coefficient
R-factor
261.28 100.13 159.18 0.11111 0.00000 0.38095 30.1 47.7
98.50 25.00 33.21 0.05556 0.00000 0.04762 19.3 51.7
299.74 51.11 10.10 0.05556 0.00000 0.07143 16.0 53.1
128.69 87.09 189.36 0.20833 0.00000 0.34524 20.3 51.0
150.39 53.74 322.67 0.36111 0.00000 0.09524 18.0 52.3
107.04 115.56 53.93 0.04167 0.00000 0.19048 14.5 51.7
185.60 87.84 196.98 0.30556 0.00000 0.26190 20.9 50.4
104.09 95.16 268.00 0.01389 0.00000 0.32143 20.3 51.2
8.84 40.91 137.04 0.26389 0.00000 0.13095 18.4 53.1
98.32 103.83 227.65 0.01389 0.00000 0.11905 24.6 49.6
The highest peak resulting from the translation function had an AMoRE 
correlation coefficient of 30.1 (3.3a). The next highest peak (not shown - for the 
same rotation function solution) had a correlation coefficient of 25.1 (2.9a).
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Having found a likely candidate for a molecular replacement solution, the top peak 
from the tr anslation function was rigid body refined and this gave a correlation 
coefficient of 48.5 and a crystallographic R-value of 41.5%. The final rigid body 
refined orientation and position of the model is given in table 6.3:
Table 6.3 Rigid body refined orientation and position of the 41kDa 
M.viridifaciens neuraminidase model, which has been re-orientated by AMoRE.
a P y a b c correlation
coefficient
R-factor
254.02 104.89 156.08 0.10 0.00 0.38 48.5 41.5
The search model was rotated in TABLING so that its principle axes of 
inertia were parallel to the box axes and translated so that the centre of mass is at 
the origin. Hence, the final stage in FITING is to convert the solution in table 6.3, 
so that it applies to the original model. The rotation and translation that was finally 
applied, is shown in table 6.4.
Table 6.4 Orientation and position of the original coordinates of the 41kDa 
portion in the 68kDa M.viridifaciens neuraminidase asymmetric unit.
a P y a b c correlation
coefficient
R-factor
32.97 54.29 217.94 -56.42 0.00 14.56 48.5 41.5
The molecular replacement solution for the position of the 68kDa form of 
M.viridifaciens neuraminidase was further verified by manual examination of 
packing between symmetry related molecules in the unit cell (Fig. 6.2), using the 
graphics package “O”. No clashes, or bad contacts between symmetry related
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molecules were apparent and this solution was subsequently used to solve the 
structure of the 68kDa M.viridifaciens neuraminidase.
F ig. 6.2 Molecular packing of the 41kDa M.viridifaciens neuraminidase search 
model in the 68kDa M.viridifaciens neuraminidase unit cell.
Discussion
The ease with which a molecular replacement solution was found for the 
68kDa form of M.viridifaciens neuraminidase reflects two major advantages in the 
way in which the search for a solution was conducted. Firstly, the search model
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was known with almost complete certainty to represent 60% of the target structure 
and therefore represented a high quality search model. Secondly, the molecular 
replacement package AMoRE is recognized as a powerful tool in molecular 
replacement and has been employed successfully in a number of cases where 
standard packages have failed.
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Chapter 7
BUILDING AND REFINING 
THE 68kDa MODEL
Rigid body refinement
The first step after determining the rigid body refined molecular 
replacement solution to the 41kDa M.viridifaciens neuraminidase search model 
was to perform a rigid body refinement of the rotated and translated model, 
implemented in X-PLOR (round 1 of refinement). All subsequent refinement was 
also performed using X-PLOR version 3.1. The refinement procedure is 
summarized in table 7.1. The free R-factor (Brunger, 1992) decreased from an 
initial value of 46.3% to 44.5% at a resolution of 3.5A. Rigid body refinement 
uses the complete energy function E TOt a l , (Appendix 2), minimizing the six 
rotational and translational degrees of freedom for specified groups of atoms.
Generating the first electron density map
Using phases derived from the rigid body refined 41kDa M.viridifaciens 
neuraminidase model, a difference Fourier map of the type 2F0-FC was generated. 
Firstly, structure factors for the model were generated using SFALL. A scale 
factor was then applied to the observed and calculated structure factors in
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RSTATS (CCP4 suite of programs), in order to put both on the correct scale. 
Using the calculated phases from the partial structure information of the model, 
the “Partial” option in SIGMAA was used to write out weighted Fourier
i ( a c a lc )
coefficients for a difference map of the type 2F0-Fce . The fast Fourier 
program FFT (CCP4 suite of programs) was then used to calculate the difference 
Fourier with the above coefficients and generate the electron density map at a 
resolution of 3.5A. The map was also solvent flattened using the WANG 
procedure and this greatly improved the quality of the map.
Inspection of the 1st electron density map
The fit of the 41kDa M.viridifaciens neuraminidase model to the 1st map 
was excellent and ihe correct side chain density was apparent (fig. 7.1). In 
addition, extra density due to the remaining 27kDa of the structure was revealed 
(fig. 7.2).
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Fig. 7.1 A typical region of the initial solvent flattened difference electron 
density map with the 41kDa M.viridifaciens neuraminidase model superimposed 
on the density. The resolution of the map is 3.5A and is contoured at la .
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Fig. 7.2 A view of the same map, showing the extra density corresponding to 
the additional 27kDa of the 68kDa structure.
The extra density at the C-terminus of the 41kDa domain revealed the 
path that the a-carbon chain would take into the next domain and the density 
appeared to indicate the presence of two domains. However the data set for the 
68kDa M.viridifaciens neuraminidase was only 57% complete to 3.5A and this 
was reflected in the overall quality of the map. The density could only be clearly 
interpretated for several residues after the C-terminal lie of the 41kDa protein and 
an overall fold for the extra 27kDa was not apparent. In order to trace the 
polypeptide backbone through the extra density, significant improvements in the 
map needed to be made.
Modelling the electron density for the extra 27kDa of protein
In order to improve the difference Fourier map obtained using starting 
phases from the molecular replacement solution, a model was required for at least 
part of the unknown structure, which would improve the overall phase 
information. To reduce the bias introduced by the 41kDa sequence, this was 
removed from the 68kDa sequence and the remaining 27kDa sequence searched 
against the SWISSPROT amino acid sequence database using FASTA in the 
GCG suite of software. The database search revealed a 34.6% amino acid 
sequence identity over a stretch of 127 amino acids with galactose oxidase from 
Dactylium dendroides, whose structure has been elucidated (Ito et aL, 1991, 
1994). The second highest identity of 30.9% within a 139 amino acid region, lay
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with the neuraminidase precursor from C. septicum. The sequence alignment of 
the 27kDa sequence against galactose oxidase is shown below in Fig. 7.3.
Fig. 7.3 Sequence alignment of the C-terminal 27kDa sequence of 68kDa 
M.viridifaciens neuraminidase (top sequence) against galactose oxidase from 
Dactylium dendroides (lower sequence). Only the region of high identity is 
shown. Residues involved in cation binding and galactose binding are boxed and 
shaded respectively (Ito et al., 1991).
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Galactose oxidase is a three domain structure, consisting almost entirely of 
(3-strands (Chapter 9) (fig. 7.4). The first domain is a (3-sandwich, consisting of a 
five stranded antiparallel (3-sheet facing a three stranded antiparallel (3-sheet. The 
second domain is the largest of the three and has the (3-propeller fold with pseudo 
7-fold symmetry. The C-terminal third domain is formed from seven (3-strands, 
which make a complicated hydrogen bond network.
From examination of the sequence alignment, the identity with the C- 
terminal part of the 27kDa sequence was shown to lie within the N-terminal
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domain 1 of galactose oxidase. Hence, domain 1 was moved manually onto the 
M.viridifaciens difference map using the graphics package O and was found to fit 
remarkably well. The galactose binding domain was then mutated to the 
M.viridifaciens sequence using the O command mutate_replace. Side chain 
density for the M.viridifaciens sequence at residues where the two sequences 
differed was evident, giving further credence to the use of domain 1 of galactose 
oxidase as a model (fig. 7.5). At this stage however, the density for the 
intervening domain linking the galactose binding and 41kDa domain could not be 
interpreted. Therefore in an attempt to improve the quality of the map, it was 
decided to refine the 41kDa and galactose binding domain and calculate a new 
map. Throughout the 3.5A refinement the 41kDa domain was kept fixed, together 
with its original B factors.
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Fig . 7.4 Orthogonal views of galactose oxidase from Dactylium dendroides. 
The catalytic domain is shown in mustard, the immunoglobulin domain in 
burgundy and the galactose binding domain in olive. A copper ion involved in 
catalysis by galactose oxidase is shown as a copper sphere and the sodium ion as 
a grey sphere.
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Fig. 7.5 Region of the 3.5A 2F0-FC electron density map with the mutated 
domain 1 of galactose oxidase superimposed on the density. Residue Arg 553 
(renumbered) in the M.viridifaciens sequence which corresponds to a Threonine 
in galactose oxidase has the correct side chain density.
Refinement and completion of building of the 68kDa
M. viridifaciens neurami n i dase
Round 2 of refinement
The galactose binding domain mutated to the M.viridifaciens sequence 
and 41kDa domain were refined in X-PLOR as rigid bodies. The free R-factor 
was 47.1% before and after the refinement.
Round 3 of refinement
The galactose binding domain was refined using PREPSTAGE in X- 
PLOR at a resolution of 3.5A. After PREPSTAGE the free R-factor for the 
model was 44.1%.The refined coordinates were then used to generate a new
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partial map, using the same protocol as described above. The corresponding 
solvent flattened map was also calculated using the WANG procedure.
Round 4 of refinement
The improved phases resulting from the inclusion of the galactose-binding 
domain in the model, improved the quality of the map significantly and it now 
became apparent that the linker domain consisted of seven (3-strands (Fig. 7.6). 
Various (3-strand structures of the right dimensions were superimposed onto the 
electron density corresponding to the linker domain in an attempt to find a model. 
These included various immunoglobulins and fibronectin modules. However it 
was not possible to find a model that unambiguously fitted the density. Therefore 
the density was traced without the aid of a model, up to the end of the first 13- 
strand. After this the density became ambiguous and so a new partial map was 
generated with the first strand incorporated as a polyalanine chain.
Fig. 7.6 Improved electron density map of the linker domain.
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Round 5 of refinement
This process was repeated, incorporating more of the polyalanine 
structure as each new partial map improved. After the whole of the linker domain 
had been built as poly alanine, the model was refined in PREPSTAGE and a new 
SIGMAA weighted map calculated. In all rounds of refinement in X-PLOR, the 
41kDa domain was fixed and the domain’s original B-factors retained. This was 
performed due to the accuracy with which the structure of the 41kDa domain was 
known and due to the poor observation to parameter ratio of the 68kDa data, 
resulting from the incompleteness of data. After this round of PREPSTAGE the 
free R-factor was 41.6%. The corresponding side chains were now added and the 
Lego commands in O were used to obtain the most appropriate main chain and 
side chain rotamers, optimising their fit to the density. The 27kDa of the structure 
was then refined in PREPSTAGE and a new SIGMAA weighted map calculated 
together with the corresponding solvent flattened map.
Round 6 of refinement
Several more cycles of manual adjustment of the positions of side chains 
were carried out, with concomitant refinement in PREPSTAGE and calculation of 
new SIGMAA weighted maps. Unweighted 2F0-FC maps generated using 
X-PLOR were also used at this stage, but did not reveal any obvious 
improvements that could be made. After the final cycle of refinement, the free R- 
factor was 26.3%. Conventional omit maps and simulated annealing omit maps 
were calculated, omitting residues in regions of interrupted or ambiguous density. 
However these gave little or no improvement over the previously calculated maps.
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Round 7 of refinement
Fortuitously, shortly after the previous round of refinement a native data 
set which was 80.7% complete (>lo) to 2.5A became available. The present 
model for the 68kDa domain was refined at a resolution of 2.5A in X-PLOR, with 
the linker domain removed and the 41kDa domain unfixed in the refinement. Due 
to the additional observations, the model was now also refined in SLOWCOOL 
and the free R-factor was 42.0% after completion of refinement. A new 2Fo-Fc 
map was generated with weighted Fourier coefficients in SIGMAA from the 
refined coordinates.
Round 8 of refinement
Careful inspection of the 2Fo-Fc electron density map confirmed that the 
connectivity of the linker domain and galactose binding domains were correct. It 
was however obvious that further manual rebuilding of certain regions, 
particularly the C-terminal end of the linker domain was required. This region was 
rebuilt, the coordinates for the linker domain added back and the model refined 
again in X-PLOR. After SLOWCOOL, the free R-factor for the model was 
37.7%.
Round 9 of refinement
Simulated annealing omit maps were now calculated, omitting 15 residues 
at a time, starting at the end of the 41kDa domain and extending up to residue 
536 of the galactose binding domain. Appropriate manual rebuilding using O was 
performed, but most of the modifications made were fairly subtle changes to the 
positions of side chains, or choice of side chain rotamers, or involved flipping
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peptide bonds. Refinement in X-PLOR gave a free R-factor of 37.6% after 
SLOWCOOL. The availability of extra observations now allowed refinement of 
B-factors. The B-factors were refined as two separate groups for main chain and 
side chains and the free R-factor dropped to 37.2%.
Round 10 of refinement
Five more cycles of manual rebuilding with concomitant refinement in X- 
PLOR gave a model with a free R-factor of 35.4%. Simulated annealing omit 
maps were calculated after each round of refinement, omitting stretches of 15 
residues over the residues with (j), (p angles in disallowed/generously allowed 
regions of the Ramachandran Plot. 2Fo-Fc maps were also calculated in X-PLOR 
after each round of refinement. In addition the location of a postulated sodium ion 
in the galactose binding domain was established (Chapter 9), the coordinates of 
which were now included in the model.
Round 11 of refinement
Individual B-factor refinement was implemented and a free R-factor of 
34.0% was obtained.
Round 12 of refinement
The model was now refined against the complete data set with a 0g cut­
off. Firstly the individual B-factor refined model was refined in PREPSTAGE 
and then individual B-factors refined. This was repeated a second time to give a 
final model with a R-factor of 21.4%.
A summary of the refinement procedure is shown in Fig. 7.7 and Table 7.1 
gives the refinement statistics.
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Fig. 7.7 Refinement of the 68kDa form of M :viridifaciens neuraminidase.
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Discussion and quality of the final model
Since a data set was initially only available to a medium resolution of 
3.5A, with a data completeness of 57% (>lo) the refinement had to be 
approached with caution. However with the availability of the 2.5A data set, the 
refinement progressed well and confirmed that the connectivity of the linker 
domain was correct. The crystallographic R-factor of the refined model is 21.4% 
for all reflections between 6 and 2.5A and the model includes residues 47 to 647 
and one sodium ion, but no water molecules. Table 7.2 summarizes the refinement 
statistics for the final model.
T a b le  7.2 Refinement statistics for the final model of the 68kDa form of 
M.viridifaciens neuraminidase.
number of non-hydrogen protein atoms 4536
number of water molecules 0
resolution range 6.0 - 2.5k
number of reflections 18,632




Average temperature factors: 
main chain 17.68A2
side chain 18.97 A2
The same tests were applied to judge the quality of the refined model as 
were used with the 41kDa M.viridifaciens neuraminidase structure (Chapter 5 
Quality of the final model). The 3D-ID score was greater than zero for all regions 
of the structure, indicating that all side chains were in favourable environments
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(fig. 7.8). The Luzatti plot for the refined structure gave a mean positional error 
of between 0.25 and 0.30A for all data between 6 and 2.5A, with a 2a  cut-off 
(fig. 7.9). Fig. 8.0 shows the Ramachandran plot for the final model produced 
using Procheck. There were 2 residues with (j), (p angles in disallowed regions of 
the Ramachandran plot and 6 residues with (|), (p angles in generously allowed 
regions.
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Fig. 7.9 Luzatti plot for the refined 68kDa model. The bold line gives the 
observed R-factor. The broken lines represent the theoretical values associated 
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Residues in most favoured regions [A$.L]
Residues in additional allowed regions [a.h.l.p] 
Residues in generously allowed regions [~a,~b,~l,~p] 
Residues in disallowed regions
Number of non-glycine and non-proline residues
Number of end-residues (excl. Gly and Pro)
Number of glycine residues (shown as triangles) 
Number of proline residues
Total number of residues
Based on an analysis of 118 structures of resolution of at least 2.0 Angstroms 
and R-factor no greater than 20%. a good quality model would be expected 
to have over 90%- in the most favoured regions.
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The various main chain and side chain parameters obtained from Procheck 
for the refined model are illustrated as a function of residue number in fig. 8.1. 
The average temperature factors for main chain and side chain atoms were 
17.68A2 and 18.97A2 respectively and the temperature factors for the refined 
model as a function of the residue number are given in fig. 8.2. The rms deviation 
in bond lengths and angles from ideality were 0.013A and 2.066° respectively for 
the final refined model.
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Fig. 8.1 ( a) Main chain and (b) side chain parameters for the refined model of
the 68kDa form of M.viridifaciens neuraminidase.
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Comparison values No. of 
No. of Parameter Typical Band band widths 
Stereochemical parameter data pts value value width from mean
a. Chi-1 gauche minus st dev 105 16.0 22.7 6.5 -1.0 BETTER
b. Chi-1 trans st dev 124 18.8 22.7 5.3 -0.7 Inside
c. Chi-1 gauche plus st dev 207 17.6 21.3 4.9 -0.8 Inside
d. Chi-1 poolec st dev 436 17.8 22.0 4.8 -0.9 Inside
e. Chi-2 trans st dev 107 20.5 23.1 5.0 -0.5 Inside
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Fig. 8.2 Temperature factors as a function of residue for the refined model of
68kDa M.viridifaciens neuraminidase.
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B-value of side-chain atoms
Residue number 
d. Secondary structure & estimated accessibility
Highlighted residues than are those 
that deviate by more than 2.0 St. devs. from ideal
Key:- Helix I ^ Beta strand Random coil Accessibility shading: Black=buried, White=accessible
c. Sequence & Ramachandran regions a Most favoured a Allowed 1 Generous I  Disallowed
AAAA&SA AA AU> (QAAAAAAAAAAAAAAAAQ AAAAAAA8AAAA&AAA HfAiSA^B8 3  AAAAA AHA +AAAAAAAAR+A AAAAAAAAAAXA A
HVYSQRQGFAGSFPGTDPADPNVLUANVATSTDGGLTWSHRTITADI TPDPGWRSRFAASGEGIQLRYGPHAGRLIQQYTI IN'AAGAFQAVSVYSDDHGR
a. Absolute deviation from mean Chi-1 value (excl. Pro)
Residue number
B-value of main-chain atoms
Max. deviation (see listing)
si. G-faetors
Qii] only I 
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a. Absolute deviation from mean Chi-1 value (excl. Pro)
Residue number
B-value of main-chain atoms
Residue number
B-value of side-chain atoms
Residue number Highlighted residues than are those
that deviate by more than 2.0 st. devs. from ideal
d. Secondary str ucture & estimated accessibility
Key:- Helix I [) Beta strand =  Random coil Accessibility shading: Black=buried, While=accessible
e. Sequence & Ramachandran regions a Most favoured a Allowed 1  Generous I  Disallowed
AAAA AAA  A  8^ S A A A A > A A A  AAAAAAAAA vI I a  AAAAAAAK* I a A  AA»AAAAftAAgBIAAAAAAAAfflAAAAA A A A A A »A A A A ^A A A A »A H B H , A
TWRAGEAVGVCMIIENKTVELSDGRVLI.NSRDSARSGYRKVAVSTDGGHS YGPVTIDRDLPDPTNNAS I IRAFPDAPAGSARAKVLLFSNAASQTSRSQGT
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a. Absolute deviation from mean Chi-1 value (excl. Pro)
Residue number
B-value of main-chain atoms
Residue number
B-value of side-chain atoms
Residue number 
d. Secondary structure & estimated accessibility
SSSSS
Highlighted residues than are those 
that deviate by more than 2.0 St. devs. from ideal
Key:- Helix I S Reta strand =  Random coil Accessibility shading: Black=buried. White=accessible
e. Sequence & Ramachandran regions A Most favoured B Allowed 1  Generous I  Disallowed
AABsAAiBAAfS* AAIZAAAAA+AAA git AAAAA A. AAAA+AAAA+A
1 RMSCDDGQTWPV SKVFQPGSMSYSTLTALPDGTYGLLYEPGTGIRYANFNLAWLCOICAPFTIPDVALEPGQQVTVPVAVTNQSGIAVPKPSLQLDASP
i. Max. deviation (see listing)






■ r.. r 11
355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445
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b. Average
a. Absolute deviation from mean Chi-1 value (excl. Pro)
Residue number
B-value of main-chain atoms
Residue number 
d. Secondary structure & estimated accessibility
Highlighted residues than are those 
tliat deviate by more than 2.0 st. devs. from ideal
Key:- fielix I ^  Beta Strand = »  Random coil Accessibility shading: Black=buried, While=accessible
e. S e q u en ce  & Ramachandran regions a Most favoured b Allowed I  Generous I  Disallowed
%AAAA nitni itti aaaaaak-a tu  AAAA AAAAAA& A A AjAAAAAA AA+AAAAAAAAAAPAAPffAAA
IWJVQGSVEPLM1 GRQAKGQVT ! TVI'AGTTI'GRYRVGATLRT S AGNASTTFTVTVGLLDQARMS I ADVDSEETAREDGRASNVIDGNFSTFVWTEWSRAD
Residue number
B-value of side-chain atoms
f. Max. deviation (see listing)
g. G-factors
&  clii4 
Omega 
Dihedrals
447 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545
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a. Absolute deviation from mean Chi-1 value (excl. Pro)
Residue number
S b. Average B-value of main-chain atoms
|  100-T     - T—     ,
oh 80  - 1 |
Residue number
a c. Averatie B-value of side-chain atoms
f  I'X'f *    -i
~  80 -
§  f>() -
J3
Residue number Highlighted residues than are those
that deviate by more than 2.0 st. devs. from ideal
d. Secondary structure & estimated accessibility
SSSSS:
Key:- Helix I % Beta strand =  Random coil Accessibility shading: Black=buried, White=accessible
e . Sequence & Ramachandran regions A Most favoured B Allowed 1 Generous I  Disallowed
$ A  ABIAAAAAAA AAAAt? AAAAAAAA+AARAAtfAAAAAAAAA BAA4 AAAA AAF+AAAAAVHAAtPAAF+AAAAAAAAAtR SSAAAAAAjAAAA. A
APGYPHKISLDLGGTHTI SGLQYTRRQNSANEQVADYE1 YTSLNGTTTOGPVASGRFTTSLAPQRAVFPARDARYI RLVALSEQTGHKYAAVAELEVEGQ








4  I J g a ^ L l . U . t J .  .1L L L l.irL j.rt:y l:I.L X It l i l l i i Tl:iJ-l..lrL.l.Overall
547 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645
c = cis-peplidc
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b. Avera.se B-value of main-chain atoms
Residue number
c. Avera.ee B-value of side-chain atoms
647
Residue number Highlighted residues than are those
that deviate by more than 2.0 St. devs. from ideal
d. Secondary structure & estimated accessibility
'$
Key;- Helix I *> Beta strand « =  Random coil Accessibility shading: Black=buried. Whitc=accessible
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THE 41kDa M . v i r i d i f a c i e n s  
NEURAMINIDASE STRUCTURE
Protein architecture
The 41kDa M.viridifaciens neuraminidase is monomeric and exhibits the 
typical neuraminidase (3-propeller fold. This consists of six four stranded antiparallel 
p-pleated sheets arranged on the blades of a propeller. In addition, there is one short 
4 residue a-helix at the C-terminus of the enzyme and two short 3io helices, as 
defined in the DSSP (Kabsch & Sander, 1983) definition of secondary structure. One 
of the 3io helices is located between residues 190 and 193 and the other is located 
between residues 327 and 329. A view down the six-fold axis of the monomer is 
shown in fig. 8.1, together with the same view down the six-fold axes of the 
neuraminidases from influenza N8, S.typhimurium and V.cholerae, for comparison.
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Fig. 8.1 A view down the six-fold axis of three bacterial neuraminidases and a 
view down the four-fold axis of one viral neuraminidase, (a) Influenza N8 
neuraminidase (b) S.typhimurium neuraminidase (c) M.viridifaciens neuraminidase 
and (d) V.cholerae neuraminidase. Note the lectin-like domains on either side of 
the central catalytic domain of V.cholerae neuramidase.
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Comparison with other neuraminidase structures
In spite of possessing a low sequence identity with other neuraminidases 
(table 8.1), the 41kDa M.viridifaciens neuraminidase shows a high degree of 
structural homology. The 41kDa form of M.viridifaciens neuraminidase has the 
highest structural homology with V.cholerae neuraminidase. The two neuraminidases 
share 26% sequence identity, yet superposition of the two structures results in a rms 
deviation of 2.31 A over 336 Ca atoms. Influenza neuraminidase of subtype N9 has 
the lowest structural similarity with the 41kDa form of M.viridifaciens
o
neuraminidase; superposition of the two structures gives a rms deviation of 3.69A 
over 296 Ca atoms. However Influenza N8 and N2 subtypes produce similar rms 
deviations with the 41kDa form of M.viridifaciens neuraminidase. Overall structural 
homologies between the 41kDa M.viridifaciens neuraminidase and all other 
neuraminidase structures known to date, are summarized in table 8.2. Rms deviations 
were generated using the program MNYFIT from the COMPOSER suite of 
modelling software(Sutcliffe et a i, 1987). MNYFIT performs the superposition of 
two or more protein structures and determines the location of structurally equivalent 
residues, using this information to define the family framework. Six topologically 
equivalent active site residue atoms were chosen for the initial superposition by 
MNYFIT. These are listed in table 8.3.
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Table 8.1 Sequence identity matrix for viral and non-viral neuraminidases.
% mhc
g9
T.cruzi V.cholerae st2 N8 N9 N2 B/Beijing B/Lee
mv1 33.44 21.77 25.92 19.22 16.23 15.39 16.19 18.30 19.77
1 M.viridifaciens neuraminidase
2 S.typhimurium neuraminidase
Table 8.2 rmsds (A) between the 41kDa M.viridifaciens neuraminidase and 
the other neuraminidase structures. The numbers in brackets are the number of 
equivalences found by COMPOSER and used in the superposition.
A V.cholerae st2 N8 N9 N2 B/Beijing B/Lee
mv1 2.31 2.59 3.57 3.69 3.65 3.23 3.20
(336) (335) (295) (296) (294) (302) (302)
1 M.viridifaciens neuraminidase 
2 S.typhimurium neuraminidase
Table 8.3 Topologically equivalent active site residues used in the initial 
superposition by COMPOSER.
mv1 V.cholerae st2 N8 N9 N2 B/Beijing B/Lee
Arg 68 Arg 224 Arg 37 Arg 118 Arg 118 Arg 118 Arg A115 Arg 116
Arg 342 Arg 712 Arg 309 Arg 371 Arg 371 Arg 371 Arg A373 Arg 374
Arg 276 Arg 635 Arg 246 Arg 292 Arg 292 Arg 292 Arg A291 Arg 292
Tyr 370 Tyr 740 Tyr 342 Tyr 406 Tyr 406 Tyr 406 Tyr A408 Tyr 409
Glu 386 Glu 756 Glu 361 Glu 425 Glu 425 Glu 425 Glu A427 Glu 428





In spite of the low sequence identity observed between bacterial 
neuraminidases (Chapter 1 Introduction), there remain two conserved sequence 
motifs found across bacterial neuraminidase sequences.
1. Asp-boxes
The 41kDa form of M.viridifaciens neuraminidase contains 5 so called Asp- 
boxes. Asp-boxes are present in all bacterial neuraminidases characterized to date 
and have the consensus sequence Ser/Thr-X-Asp-[X]-Gly-X-Thr-Trp/Phe. The five 
Asp-boxes occur in the same topologically equivalent positions as observed for the 
other two bacterial neuraminidases (V.cholerae and S.typhimurium): at the turns 
between the third and fourth strands of each sheet. The Asp-boxes are once again 
distant from the active site and have no role in catalysis. The aromatic side chains of 
Asp-boxes tuck neatly in between adjacent strands and the aspartic acid side chains 
point out into solvent. The five Asp-boxes of M.viridifaciens neuraminidase were 
superimposed with respect to the first Asp-box using Lsq_explicit and Lsq_improve 
in O and table 8.4 summarizes the results. Lsq_explicit performs a least squares 
comparison of two structures via explicit atoms. Lsq_improve improves on a given 
transformation produced by Lsq_explicit. Lsq_improve employs an algorithm 
involving a search for structure fragments that can be aligned within a given cut off 
limit and tries to improve the transformation and the matched atoms. The algorithm 
cycles until either the same set of atoms are selected or until 10 cycles are made.
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Table 8.4 Asp-box similarity in the 41kDa form of M.viridifaciens neuraminidase. 
Values are given as rmsds (A) between Asp-box 1 (Dl) and Asp-boxes 2 (D2)-5 




D l D2 D3 D4 D5
D l 0.00 0.18 0.32 1.87 0.19
D l: S T D G G R T W  
D2: S T D G G L T W  
D3: S D D H G R T W  
D4: S T D G G H S Y  
D5: S C D D G Q T W
It is apparent from table 8.4 that the outlier of the five Asp-boxes is Asp-box 
4, which has a rmsd of 1.87A with Asp-box 1. In Asp-box 4 a tyrosine replaces the 
tryptophan which is conserved in the other four Asp-boxes. The OH of the tyrosine 
hydrogen bonds to the ND1 atom of a histidine two residues prior to the tyrosine in 
the sequence. This additional hydrogen bonding, not present in the other Asp-boxes, 
results in a distortion of the loop from its normal conformation. Since the catalytic 
activity of the enzyme is not affected, the Asp-box motif appears to merely dictate 
the fold and integrity of the propeller and may not be involved in a secretory 
mechanism.
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2. The FRIP motif
The sequence Phe-Arg-Ile-Pro, or small variations on this theme, occurs at 
the N-terminal end of all bacterial neuraminidase sequences. In the case of the 
neuraminidase from M.viridifaciens, the Phe is replaced by Tyr. The conserved 
Arginine residue in the FRIP motif represents one of the catalytic triad of arginines in 
the active site, which stabilizes the carboxylate group of sialic acid. A sequence 
alignment of the 41kDa form of M.viridifaciens neuraminidase against the sequence 
of the neuraminidase from S.typhimurium and V.cholerae is shown in fig. 8.2. The 
FRIP and Asp-box motifs are highlighted.
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Fig. 8.2 Sequence alignment of three bacterial neuraminidase sequences: 41kDa 
M.viridifaciens, S.typhimurium and V.cholerae neuraminidase (neuraminidase 
domain only). Conserved catalytic residues are marked with an asterix and the FRIP 
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The Active site - obtaining the inhibitor complex
The position of the active site in the 41kDa form of M.viridifaciens 
neuraminindase was confirmed by soaking a solution of the inhibitor 2-deoxy-2,3- 
dehydro-N-acetylneuraminic acid (DANA) (fig. 1.3, Chapter 1) at a concentration of 
5mM into a 41kDa crystal for 3 hours and collecting inhibitor complex data.
Data collection and analysis
All inhibitor data were collected from the in-house rotating anode source and 
a data set which was 83.0% complete (>lo) to 2 k  was obtained by merging two 
separate data sets in XSCALE. All data processing was performed using the XDS 
suite of software. The data collection statistics are given in table 8.5.
Parameters for data collection were as follows: 
crystal to detector distance = 10cm 
X-ray generator settings = 50kV, 80mA 
exposure time = 120 - 180 seconds/frame 
20 swing angle = 20° 
temperature « 21°C
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-10.0 1169 230 99.1 96.14 4.9
10.0-5.0 8403 1413 99.1 95.8 4.5
5.0 - 4.0 8832 1467 99.3 97.3 4.8
4^ O i o 22549 4074 98.7 94.6 5.8
3.0 - 2.5 23324 4963 95.2 85.7 8.3
2.5 - 2.0 28763 8219 67.4 52.7 11.2
©o - 2.0 93043 20366 83.0 72.8 6.3
cell dimensions a b c a  3 Y
48.00 82.86 84.94 90.00 90.00 90.00
aRi =
XX, I U , - I J
hi
Obtaining the 2A difference Fourier map
Structure factors for the final refined model of the 41kDa form of 
M.viridifaciens neuraminidase were generated to 2 k  using SFALL. The derivative 
data set was converted to lcf format using X2L and then converted to mtz format 
using LCF2MTZ. Both the derivative and native mtz files were then merged using 
MTZUTILS and the merged reflection file scaled in LOCAL. A difference Fourier 
map was then generated with Fourier coefficients F DAn a - F 0 e,acalc using FFT. The 
map was extended in EXTEND to cover the region of the molecule of interest.
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Building and refining the inhibitor complex structure
The difference Fourier map clearly revealed density due to scattering 
contributions from the inhibitor alone. Waters in, or close to the electron density 
were removed and the inhibitor structure was rotated and translated into the map 
manually, using the graphics package ‘O’. Refinement of the complex was then 
implemented in X-PLOR. Rigid body refinement of the complex did not improve the 
fit of the inhibitor to the electron density and was therefore discarded. After one 
round of PREPSTAGE, SLOWCOOL and individual B-factor refinement with a Og  
cut-off, the R-factor was 15.9%. The refined inhibitor complex has 2 residues in 
generously allowed regions of the Ramachandran plot and zero residues in 
disallowed regions. The average main chain temperature factors were 13.45A2 and 
the average side chain temperature factors were 21.29A2. The average temperature 
factors for DANA were 12.9A2. A flow chart summarizing how the refined complex 
structure was obtained is shown in fig. 8.3.
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insert DANA into map ^  difference fourier map
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B-factors in the active site
There was little change in the position of active site amino acid side chains on 
binding the inhibitor and the active site appears to be fairly rigid, as observed in other 
neuraminidases. Evidence for this comes from examining the B-factors of the active 
site residues. The B-factors of the active site residues in the native and inhibitor 
complexed structures are very similar, as shown in table 8.6. The B-factors of the 
terminal atoms of the active site residues in either the native 01* complexed structures
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are significantly lower than those of a typical amino acid. The B-factor of the Ne 
atom of the active site residue Arg 68 in the complexed structure is 10.8A2, in 
comparison with a B-factor of 60.2A2 for the Ne atom of Arg 61. Similarly in the 
native structure, the B-factor of the OE2 atom of the active site residue Glu 386 has 
a value of 8.5A2, in comparison with 45A2 for the OE2 atom of Glu 48.
Table 8.6 Average B factors of the active site residues in the native and inhibitor 
complexed 41kDa form of M.viridifaciens neuraminidase.
Active site residue Native 41kDa enzyme 
(A2)
41kDa enzyme complexed with 
inhibitor (A2)
68 Arg 11.0 10.0
92 Asp 26.8 34.0
131 Asp 12.4 12.4
276 Arg 13.4 10.6
342 Arg 11.8 13.5
370 Tyr 6.1 4.9
386 Glu 7.5 10.0
Overall average B 
factor (A2)
12.7 13.6
The Active site-interactions with the inhibitor
The similarities and differences between the interactions of the inhibitor with the 
active site in the 41kDa form of M.viridifaciens neuraminidase and in other 
neuraminidases are discussed in detail below. Fig. 8.4 shows the difference Fourier 
map, with DANA superimposed on the density. A summary of the interactions
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between DANA and the active site residues in the 41kDa form of M.viridifaciens
neuraminidase is given in table 8.7.
A) Interactions with the glycerol side chain of DANA. In M.viridifaciens 
neuraminidase, there is one strong hydrogen bond to 08  and one strong and one 
weak hydrogen bond to the 0 9  of DANA from Asp 259. Similarly, the viral enzyme 
has two strong hydrogen bonds to the 08  and 0 9  of the glycerol group of NANA 
and DANA, but the Asp is replaced by a Glu. Asp 637 of V.Cholerae neuraminidase 
could form interactions to the 08  and 09  and Asn 318 with 07, but since no 
inhibitor complex has yet been solved this can only be speculation. In contrast, 
S.typhimurium neuraminidase has only one weak hydrogen bond to the glycerol 
group; from Trp 128 to 09. S.typhimurium neuraminidase is known to have a 
solvent channel around the glycerol group of the inhibitor/substrate which was 
postulated to explain why the enzyme proceeds with inversion of configuration at the 
anomeric C2 of the sialic acid, since a water molecule would be able to attack 
underneath from the p-face of the sugar ring. However, M.viridifaciens 
neuraminidase is also thought to proceed by inversion of configuration (M. Sinnott - 
personal communication), yet it has stabilizing hydrogen bonds to the 08  and 0 9  of 
the glycerol group. Asp 259 must therefore be distant enough from the DANA to 
allow a water molecule to approach from the p-face, to initiate catalysis by inversion 
of configuration, whilst still maintaining hydrogen bonds to the glycerol group. There 
is however some conflicting evidence as to whether M.viridifaciens neuraminidase
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does indeed proceed by inversion of configuration. This will be discussed in more 
detail in the subsequent section.
B) Interactions with the 0 4  of DANA. Interactions with the 0 4  of DANA in the 
active site of M.viridifaciens neuraminidase strongly resembles that in S.typhimurium 
neuraminidase and V.cholerae neuraminidase, but with one extra strong hydrogen 
bond to the 04. The 04  of DANA has strong hydrogen bonds to Asp 131, Asp 92 
and Arg 87.These are replaced by Arg 245 and Asp 292 in V.cholerae neuraminidase 
and by Arg 56, Asp 62 (weakly hydrogen bonding) and Asp 100 in S.typhimurium 
neuraminidase. The presence of only a weak hydrogen bond to the 0 4  in the viral 
enzyme has enabled the rational design of potent inhbitors, which bind in this pocket.
The active site of the influenza enzyme has long been an attractive target for 
drug design, due to the ineffectiveness of vaccines as described in Chapter 1 and 
because of the invariant nature of the amino acids lining the active site. Twelve of 
these invariant residues (N9 subtype numbering); Arg 118, Glu 119, Asp 151, Arg 
152, Trp 178, lie 222.. Glu 276, Glu 277, Arg 292, Arg 371, Asn 294 and Tyr 406 
are in contact with the inhibitor DANA in the complex and a further six residues; Ser 
179, Arg 224, Glu 227, His 274, Gly 348 and Glu 425 are in the second shell of 
active site residues, stablilzing the binding site. In the active sites of the bacterial 
enzymes, a conserved arginine and aspartic acid form hydrogen bonds to the 0 4  on 
the inhibitor. However these interactions are absent in the viral enzyme, resulting in a 
pocket close to the 04. This pocket has been filled by replacing the 4-hydroxyl on
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DANA with a guanidinium group to produce a rationally designed inhibitor against the 
influenza enzyme (fig. 8.5). The interactions between the active site residues of 
influenza virus neuraminidase and bound DANA are shown in fig. 8.6.
C) Interactions with the 0 6  of DANA. There is one strong hydrogen bond from Tyr 
370 to the 06  in the M.viridifaciens-inhibitor complex. S.typhimurium neuraminidase 
has one hydrogen bond to a water molecule and the V.cholerae enzyme may have 
hydrogen bonds to the 06  of DANA from Tyr 740 and Asp 250. The viral enzyme has 
one weak hydrogen bond to the 06 from the OE1 of Glu 279 and one strong hydrogen 
bond from Tyr 406.
D) Interactions with the Carboxylate group of DANA. Interactions between the 
carboxylate group of the inhibitor and the active site are common to all neuraminidase 
structures studied to date. Three arginines, Arg 68, Arg 276 and Arg 342, form 
hydrogen bonds in a plane with the carboxylate group of the inhibitor. Arg 68 is 
stabilized by Glu 386 through a hydrogen bond between the Ne of the Arginine and 
081 of the Glutamic acid. Tyr 370 and Glu 260 hydrogen bond with each other and sit 
beneath and close to the C1-C2 bond of the inhibitor.
E) Interactions with the 0 7  of DANA. The 07 of DANA makes two strong 
hydrogen bonds to two water molecules and a weak hydrogen bond to one further 
water molecule. As with the viral and S.typhimurium enzymes there are no
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interactions with protein atoms. However the V.Cholerae enzyme may make 
hydrogen bonds to Asp 250 and Asn 318.
F) Interactions with the N5 of DANA. The N5 atom of DANA makes one strong 
hydrogen bond to the OD1 atom of Asp 131. Similarly the S.typhimurium enzyme 
makes a hydrogen bond from the OD2 atom of Asp 100 to N5 and the V.Cholerae 
enzyme may form a hydrogen bond between the N5 and Asp 250. The viral enzyme 
makes no interactions with the N5 atom of DANA.
G) Interactions with the 010  of DANA. The 010 of DANA makes one strong 
hydrogen bond to a water molecule. In contrast the viral enzyme makes hydrogen 
bonds to Asp 152 and Arg 153. In the S.typhimurium enzyme, the 010 interacts with 
one water molecule. The V.Cholerae enzyme may make hydrogen bonds to Asp 250 
and Asn 318.
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Table 8.7 Summary of the interactions between the bound inhibitor DANA and 
active site residues in the 41kDa form of M.viridifaciens neuraminidase. Equivalent 
residues in the Influenza, V.Cholerae and S.typhimurium enzymes are given and 
differing equivalent residue types are given.
DANA mv1 atom distance Equivalent residues in:
atom (A) st2 vc3 influenza4
OlA Tyr 370 OH 3.35 342 OH 740 OH 406 OH
Arg 68 NH1 2.76 37 NH2 224 NH1 118NH2
Arg 68 NH2 2.97 37 NH1 224 NH2 118 NH1
Arg 342 NH1 2.85 309 NH1 712 NH1 371 NH2
OIB Tyr 370 OH 3.37 342 OH 740 OH 406 OH
Arg 276 NH1 3.59 246 NH2 635 NH2 292 NH1
Arg 276 NH2 3.21 246 NH1 635 NH1 292 NH2
Arg 342 NH1 3.50 309 NH1 712 NH1 371 NH2
Arg 342 NH2 2.93 309 NH2 712 NH2 371 NH1
04 Aspl31 OD2 2.75 100 OD1 250 OD2 Glu 120 OE1
Asp 92 OD1 2.60 62 OD2 Arg 245 NH1
Arg 87 NH2 3.11 56 NH2 245 NH2
water 581 01 3.30 - -
06 Tyr 370 OH 3.09 - 740 OH Tyr 406 OH
water 773 Ol 3.40 690 01 Asp 250 OD1 Glu 279 OE1
07 water 773 Ol 2.90 689-691 Asn 318 ND2 -
water 772 01 3.57 O l Asp 250 OD1
water 774 O l 3.01
08 Asp 259 OD1 2.69 water 694 
& 688 01
Asp 637 OD2 
Glu 619 OE2
Glu 279 OE1 
Glu 278 OE2
09 Asp 259 OD2 2.90 Tip 128
Nel
- Glu 278 OE1
010 water 582 Ol 2.69 689
01
Asp 250 OD1 
Asn 318 OD1
Asp 152 OD1 
Arg 153 NH1 
Arg 153 NE
N5 Asp 131 0D1 2.93 100 OD2 250 OD1 -
1 M.viridifaciens neuraminidase
2 S.typhimurium neuraminidase
3 V.cholerae neuraminidase. N.B There is no crystal structure for the neuraminidase 
from V.cholerae complexed with inhibitor. The interactions given above for 
V.cholerae with DANA are the results of modelling studies only.
4 Influenza virus neuraminidase subtype N9.
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Fig. 8.4 Stereo view of the difference Fourier map at 2A, with coefficients F Da n a -  
F0e,acalc and the refined coordinates of DANA superimposed on the density. The map 
is contoured at 3.5a.









Fig. 8.6 Interactions between the active site residues of influenza virus 
neuraminidase (subtype N9 numbering) and the inhibitor DANA. Some active site 
residues have been omitted for clarity.
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The differences between the M.viridifaciens and the other bacterial and viral 
neuraminidase active sites seem to indicate that the sialic acid in M.viridifaciens 
neuraminidase is bound more tightly than in any of the other neuraminidases. It was 
previously suggested that a possible explanation for a much higher turnover in 
salmonella as compared with the viral enzyme is the stabilization of the glycerol chain 
by hydrogen bonds in the viral enzyme, product release being the limiting factor in 
catalysis (Crennell et al., 1993). However the bound DANA in M.viridifaciens 
neuraminidase is located deeper in the active site than in the salmonella enzyme, and 
has more stabilizing hydrogen bonds, yet the M.viridifaciens neuraminidase has a high 
activity; being at least 200 units/mg protein. It is therefore unlikely that product release 
is the rate limiting factor in catalysis by M.viridifaciens neuraminidase.
Substrate specificity and enzyme mechanism
In common with many of the bacterial neuraminidases M.viridifaciens 
neuraminidase can cleave a2-3, a2-6, and a2-8 linked sialic acids. In contrast to the 
other bacterial neuraminidases S.typhimurium neuraminidase has a 260-fold kinetic 
preference for a2-3 linkages over a2-6 linkages similar to the influenza enzyme. This 
variation in substrate specificity appears to be due to steric hindrance contributions 
alone arising from the variability of the lengths of the loops around the active site. 
Table 8.8 shows the substrate specificity for those viral and non-viral neuraminidases 
whose structures have been determined.
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Table 8.8 The variable substrate specificity of the neuraminidases. Values are given 
as relative cleavage rates (%). Only those neuraminidases whose structures have 
been determined are included.
a(2-3) a(2-6) a(2-8) references
M.viridifaciens 100 253 125 Sakurada et al., 
1992
V. cholerae 100 53 30 Corfield et al., 
1993




100 <1 3 Corfield et al., 
1993, Corfield 
et al., 1982
Substrates used were: a(2-3), Neu5Aca(2-3)Galp(l-4)Glc; a(2-6), Neu5Aca(2- 
6)Galp(l-4)Glc; a(2-8), colominic acid.
The mechanism of catalysis of M.viridifaciens neuraminidase has been 
investigated using optical rotation and kinetic isotope effects. Like S.typhimurium 
neuraminidase, M.viridifaciens neuraminidase also proceeds by inversion of 
configuration at the anomeric C2 of the substrate (Guo & Sinnott, 1993 and M. 
Sinnott - personal communication). In contrast it has been shown that the 
neuraminidases from V.cholerae (Guo & Sinnott, 1993) and influenza (Chong et al., 
1992) proceed by overall retention of configuration. The situation is unclear 
however, since a recent nmr study of S.typhimurium neuraminidase showed that the 
enzyme catalysed the cleavage of sialic acid with overall retention of configuration 
(Wilson et al., 1995). In addition other nmr studies on the neuraminidase from 
M.viridifaciens, S.typhimurium and the small Cpeifringens isoenzyme show a
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mixture of retention and inversion of configuration (M. Sinnott - personal 
communication), whereas the V.cholerae neuraminidase is definitely retentive.
The mechanism of catalysis by influenza virus neuraminidase has been studied 
in most detail. Kinetic isotope methods (Chong et al., 1992), nmr (Chong et al.,
1992; Janakiraman et al., 1994), and a molecular dynamics simulation of the enzyme- 
complex (Taylor & von Itzstein, 1994) have been used in order to further an 
understanding of the enzyme mechanism. A scheme has been proposed involving an 
endocyclic sialosyl cation intermediate (Chong et al., 1992). Fig. 8.7 summarizes a 
possible mechanism for hydrolysis of the substrate by the neuraminidase from 
influenza virus. The binding of the sialic acid to the neuraminidase involves 
considerable distortion of the pyranose ring but the extensive hydrogen bonding 
network to the substrate compensates for the free energy lost. In solution, the sialic 
acid is in the chair conformation, but upon binding the pyranose ring adopts a 
pseudoboat conformation. The planar nature of the sugar around the carboxylate 
carbon and the ring atoms 06, C2 and C3 activates the sialic acid for hydrolysis. At 
the optimum pH for catalysis by influenza virus neuraminidase, the hydrolysis of the 
substrate proceeds with substantial positive charge developing at the reaction centre 
in the transition state for the formation of the sialosyl-enzyme intermediate. The 
binding site of the substrate involves a protonated Arginine. The positive charge 
which develops in the sialosyl cation transition state could be stabilized by the 
neighbouring negative charge of the carboxylates. The catalysis is probably solvent 
mediated and may involve water hydrogen-bonded to an Aspartic acid in an enzyme 
mediated proton transfer in a SNl-type mechanism. The product of the reaction,
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sialic acid, is initially released as the a-anomer which converts to the 
favourable (3-anomer in solution by mutarotation (fig. 8.8).
Fig. 8.7 Proposed mechanism for catalysis by neuraminidase from influenza virus 













































THE 68kDa M . v i r i d i f a c i e n s  
NEURAMINIDASE STRUCTURE
Protein architecture
The 68k:Da form of M.viridifaciens neuraminidase (fig. 9.1) possesses three 
domains (fig. 9.2). The 41kDa p-propeller domain, a domain with the immunoglobulin 
fold and a domain with high homology to the galactose binding domain of galactose 
oxidase from Dactylium dendroides. The 41kDa domain of 68kDa M.viridifaciens 
neuraminidase shows very little difference to the 41kDa enzyme in isolation (Chapter
o
8) and the two 41kDa domains have a rmsd of 0.4A over 358 C a atoms when 
superimposed using the program MNYFIT in the COMPOSER suite of software. The 
only significant structural change between the 41kDa domain of the 68kDa form of 
M.viridifaciens neuraminidase and the isolated 41kDa form is in residues 402-404 
which move to connect to the linker domain.
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Fig. 9.1 The 68kDa form of M. viridifaciens neuraminidase. Domain 1 is shown in 
mustard, domain 2 in burgundy and domain 3 in olive.
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Fig. 9.2 The three domains of 68kDa M.viridifaciens neuraminidase. Domain 1 (a) 
is the 41kDa P-propeller domain, domain 2 (b) is the linker domain with the 
immunoglobulin fold and domain 3 (c) is the galactose binding domain. The view is 
orthogonal to fig. 9.1.
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The linker domain
The second domain leaves the 41kDa domain at residue 405 and enters the 
galactose binding domain at residue 506. This domain, termed the linker domain, 
consists of a (3-sandwich of one (3-sheet with 4 antiparallel strands over one (3-sheet 
with 3 antiparallel strands (Fig. 9.2 (b)) and has a well-packed hydrophobic interior. 
Following a search using the program PROTEP (P. Artymuik personal comm.) the 
fold of the linker domain was found to most resemble that of the immuoglobulin 
family, particularly the immunoglobulin variable domain. Both the variable and 
constant immunoglobulin domains have been described as a Greek key P-barrel, 
subclass “simple” (Richardson, 1981). The immunoglobulin structural domains have 
between 7 and 9 antiparallel p-strands which form a barrel. The barrel is divided into 
two distinct p-pleated sheets since the hydrogen bonds do not go around the barrel and 
so the barrel appears as a P-sandwich. However in contrast to the majority of 
immunoglobulin folds, the linker domain forms an almost cylindrical 7-stranded P- 
barrel structure, which is stablilised by the first strand (strand a in immunoglobulin 
nomenclature (Bork et al., 1994)) forming hydrogen bonds with strands b and g.
Strand a is able to hydrogen bond both strands b and g by having a proline halfway 
along (Pro 411), which changes the strand direction from the b strand to the g strand 
on the opposite sheet. The linker domain does not contain any disulphide bonds and its 
sequence does not possess the consensus shown by immunoglobulin folds. The fold of 
the linker domain is therefore another variation on that of the immunoglobulins. 2-D 
topology diagrams illustrating the observed hydrogen-bonding pattern and strand 
topology in the immunoglobulins are shown in fig. 9.3. Using the program PROTEP,
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structural homologies to the linker domain were also found with the C-terminal domain 
of CD4 and the N-terminal domain of the chaperone protein PapD (fig. 9.4). The latter 
homology is interesting in that the strand a of PapD also “dog-legs” to form hydrogen 
bonding to both strands b and g, leading to a more cylindrical barrel as found in the 
linker domain (Holmgren & Branden, 1989).
Domains with the immunoglobulin-like fold have been reported in a number of 
non-immunoglobulin structures, including matrix proteins e.g. tenascin (Leahy et al., 
1992b), cell surface receptors e.g. CD2 (Driscoll et al., 1991; Jones et al., 1992), CD8 
(Leahy et al., 1992a) and interestingly galactose oxidase from Dactylium dendroides. 
With the large number of structures falling into the class of the immunoglobulin fold 
and with the huge number of proteins with sequences related to that of proteins having 
the immunoglobulin fold, the immunoglobulin-like domain is probably the most 
widespread protein module, at least in animals (Doolittle & Bork, 1993).
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Fig. 9.3 2 -D topology diagrams illustrating the observed hydrogen-bonding patterns 
in the immunoglobulins. Immunoglobulin constant domains have 7 strands in the 
topology shown as C-type. The variable domain, V-type, has an additional hairpin cv- 
cvv between strands c and d, with strand a having two alternative locations. Strand a 
can either be part of the back sheet (antiparallel pairing with strand b), or part of the 
front sheet (parallel pairing with strand g). A switched, S-type, fold can also occur. 
Here the 4th strand has switched sheets (d to cv ). An 8 stranded hybrid, h-type, 
between types C and S is also possible. This has both strands c ' (front sheet) and its 
direct continuation strand d (back sheet), so that both sheets have 4 strands. The linker 








Fig. 9.4 MOLSCRIPT drawing of the chaperone protein PapD. The two 
immunoglobulin domains are each composed of two (3-sheets, with strands a b e 
forming one (3-sheet and strands c f g forming the second (3-sheet.
The Galactose binding domain
The polypeptide backbone leaves the linker domain at residue 506 and enters 
the final domain which extends to residue 647. This latter domain has been termed the
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galactose binding domain due to its high structural and sequence homology with 
domain 1 of galactose oxidase from Dactylium dendroid.es. As summarized in Chapter 
7, galactose oxidase consists of three domains. Domain 1 has the jelly-roll motif and 
consists of a P-sandwich, with a five-stranded antiparallel p-sheet facing a three- 
stranded antiparallel p-sheet. Domain 2 contains 28 p-strands and one short a-helix. 
The residues implicated in catalysis are located in this domain. This domain has the p- 
propeller fold, with pseudo 7-fold symmetry as compared with the 6-fold symmetry 
found in the neuraminidases. The C-terminal domain 3 of galactose oxidase consists of 
a bundle of seven p-strands which make a complicated hydrogen bonding network 
surrounding a hydrophobic core.
The galactose binding domain of 68kDa M.viridifaciens neuraminidase has the 
same fold as domain 1 of galactose oxidase, consisting of a p-sandwich fold where a 
five-stranded antiparallel p-sheet faces another three stranded antiparallel p-sheet (fig. 
9.2 (c)). The sequence homology between the galactose binding domains from the two 
enzymes has been discussed in Chapter 7 and upon superposition using MNYFIT in 
COMPOSER, the two domains gave a rmsd of only 1.13A over a superposition of 136 
C a atoms.
Domain 1 of galactose oxidase is known to have a binding site for a small 
cation. This cation was assigned a sodium ion in galactose oxidase since it was the 
abundant cation in solution (Ito et al., 1994). However the binding site is not very 
specific for the cation since it was observed that other cations could replace the sodium 
ion (Ito et al., 1994). The presence of a cation binding site in the galactose binding 
domain of the 68kDa form of M.viridifaciens neuraminidase was also established (fig. 
9.6). The binding site is located in a very similar position to that in the galactose
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oxidase, and the ligands are the same. The cation maintains the conformation of the 
loop (residues 528-536) and the coordination to the ligand is a pentagonal bipyramidal 
configuration, as in galactose oxidase. A comparison of the ligands for the cation is 
given in table 9.1. Fig. 9.5 shows a sequence alignment of galactose oxidase domain 1 
with domain 3 of the 68kDa form of M.viridifaciens neuraminidase, highlighting those 
residues involved in cation and galactose binding in galactose oxidase which are 
conserved in the neuraminidase. The alignment shown here was produced using the 
BESTFIT program in the GCG suite of software and as such differs from the 
alignment shown in Chapter 7, Fig. 7.3, which was produced using the program 
FASTA. However the two different programs did not alter the way in which the 
residues involved in cation and galactose binding aligned.
Fig. 9.5 Sequence alignment of domain 1 of galactose oxidase with domain 3 of the 
neuraminidase. Residues involved in cation and galactose binding in galactose oxidase 
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Table 9.1 (a) Ligands for the cation in galactose oxidase.
First shell of ligands (2.0 - 2.4A)
residue atom ion - ligand 
distance (A)
Lys 29 main chain oxygen 2.14
Thr 37 main chain oxygen 2.01
Asn 34 main chain oxygen 2.22
Ala 141 main chain oxygen 2.36
Asp 32 OD1 2.28
Second shell of ligands (^2.6A)
residue atom ion - ligand 
distance (A)
Thr 37 OG1 2.61
Glu 142 OE2 2.62
(b) Ligands for the cation in the galactose binding domain of the neuraminidase.
First shell of ligands (2.0 - ~2.4A)
residue atom ion - ligand 
distance (A)
Asn 528 main chain oxygen 2.12
Thr 536 main chain oxygen 2.48
Asn 533 main chain oxygen 2.36
Ala 639 main chain oxygen 2.32
Second shell of ligands (~2.6A)
residue atom ion - ligand 
distance (A)
Asp 531 OD1 2.67
Glu 640 OE1 2.59
Thr 536 OG1 2.55
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Fig. 9.6 Stereo view o f the cation binding site in the galactose binding domain o f
68kDa M. viridifaciens neuraminidase.
Domain 1 of galactose oxidase was known to bind galactose with low affinity 
(Ito et al., 1994). However this galactose binding site is not likely to be the active 
site, being some 40A from the copper site and is therefore a secondary site. Hence in 
order to see whether the galactose binding domain of the 68kDa form of 
M. viridifaciens neuraminidase also possessed an affinity for galactose, a crystal of 
the native protein was soaked in a solution of 50mM galactose for 4 hours and a data 
set collected.
Collecting data from the 68kDa crystal soaked in galactose
Data was collected using the same native “magic” 68kDa crystal which had 
previously yielded 2.5A data (Chapter 3), but soaked in 50mM galactose for 4 hours. 
Data was collected on station X31 at the DESY synchrotron, Hamburg, on station 
X31 at a wavelength of 0.993A. Data was collected in 1° frames with exposure times
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between 170 and 300 seconds. Diffraction extended to 2.5A, and was 62.1% complete 
(>lo). Data collection statistics are shown in table 9.2.
Obtaining the 2.5A difference Fourier map and refining the enzyme-galactose 
complex
The 2.5A difference map for the galactose was generated in the same manner 
as for the inhibitor 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA) with the 
41kDa M.viridifaciens neuraminidase (Chapter 8). With the difference map contoured 
at 3a the presence of difference density due to contributions from the galactose alone 
clearly revealed the galactose binding site. The galactose structure was manually 
rotated and translated onto the difference map using the graphics package ‘O’ in order 
to find the best fit of the molecule to the density. Refinement of the complex was then 
implemented in X-PLOR. Rigid body refinement of the complex reduced the R-factor 
from 31.2% to 28.9%. A single round of least squares refinement in PREPSTAGE 
with a 0a cut-off gave a final R-factor of 22.8%. Fig. 9.7 shows the refined position of 
the galactose superimposed on the difference electron density.
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6.76 - 5.38 788 60.6 60.4 3.7
4.27 - 3.97 829 64.0 63.3 4.4
3.55-3.39 831 64.6 63.3 5.6
3.15-3.05 835 65.8 64.2 6.8
2.89 - 2.82 877 66.4 61.9 8.3
2.69 - 2.64 874 65.9 60.4 11.3
2.54 - 2.5 366 65.9 9.5 13.5
00-2.5 16304 62.1 58.6 5.3
cell dimensions a b c a  3 y
50.87 116.99 60.00 90.00 95.60 90.00
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Fig. 9.7 Stereo view of the difference Fourier map at 2.5A, with coefficients Fgaiactose- 
F0eiacalc and with the refined coordinates of the galactose superimposed on the density. 
The map is contoured at 3 a.
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Analysis of the sugar binding site
The wall of the galactose binding pocket in galactose oxidase consists of a 
hydrophilic half and a hydrophobic half. Tyr 43 and Trp 137 in the hydrophobic half 
interact with the carbon backbone of galactose. Asn 25, His 40, Arg 73 and Asn 79 in 
the hydrophilic half form several hydrogen bonds to the 03  and 0 4  of the galactose. In 
the neuraminidase, interactions between the galactose and binding site residues are 
subtly different (fig. 9.8). In the hydrophobic half, Tyr 43 is replaced by Trp 542, 
which makes hydrogen bonds from the carbonyl oxygen to the 0 6  of galactose. Trp 
137 is replaced by Tyr 635, which is too distant to form hydrogen bonds to the 
galactose. In the hydrophilic half Asn 25 is replaced by Arg 525, quite distant from the 
galactose, His 40 is replaced by His 539 making no hydrogen bonds, Arg 73 is 
replaced by Arg 572 which makes hydrogen bonds to the 03  and 0 4  of galactose and 
Asn 79 is replaced by Asn 577, too distant to make hydrogen bonds.
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Fig. 9.8 Interactions between bound galactose and ligands in the 68kDa form of 
M.viridifaciens neuraminidase. Although the residues within the binding pocket are 
conserved with galactose oxidase, the ligands differ.
Mobile modules
It has been recognized for some time that many proteins consist of a small set 
of modular elements. A domain (module) with very similar fold is often found in many 
different proteins. By creating new proteins with the components of other ones, the 
potential for protein diversity could increase. Rossmann first realized this when he 
solved the structure of lactate dehydrogenase (Rossmann et al., 1974). He discovered 
that the co-factor binding domain had counterparts in other dehydrogenases and these 
became known as having the Rossmann fold. Rossmann also noticed that these 
homologous domains did not necessarily occur in the same relative parts of the 
molecules, suggesting gene shuffling events. As a result Rossmann proposed the theory 
of mobile modules; in that proteins were composed of domains (or modules) that had
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evolved early in life’s history. By moving as discrete units from one protein to another 
during evolution, these mobile modules increase protein diversity. The number of 
domains being recognized as mobile modules is increasing and well documented 
examples include the immunoglobulin family, fibronectin types 1, 2 and 3 and the lectin 
family. The linker and galactose binding domains of 68kDa M.viridifaciens 
neuraminidase are examples of such mobile modules.
The similarity of the sequences from the non-catalytic domains of 68kDa 
M.viridifaciens neuraminidase and the amino terminal domain of galactose oxidase has 
already been reported (Bork & Doolittle, 1994) (Chapter 7). However there is no 
sequence resemblance between the catalytic domains of the two enzymes, in spite of 
the fact that both are now known to have similar folds; domain 2 of galactose oxidase 
has a 7-sheet (3-propeller. This suggests that the non-catalytic domains of 
M.viridifaciens neuram.nidase were shuffled into their present location after the 
divergence of the catalytic domain. Following elucidation of the crystal structure of 
68kDa M.viridifaciens neuraminidase, the non catalytic domains were revealed to 
consist of a domain with the immunoglobulin fold and a domain within which the 
sequence similarity to galactose oxidase lay.
The immunoglobulin fold strongly resembles that of fibronectin type III 
domains, another class of mobile modules. This domain is often found in animal 
proteins, but is also found in bacterial proteins. The enzyme occurs as a distinct seven- 
stranded (3-sandwich. The fibronectin type III domain has been well studied (Little et 
al., 1994, Doolittle & Bork, 1993). It appears from phylogenetic studies that bacteria 
have acquired Fn3 units by horizontal transfer between themselves (Little et al., 1994). 
This has been taken further with the proposal that the initial acquisition of the Fn3 unit
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in bacteria was from a eukaryotic source, via transformation. A scenario may be 
envisaged whereby a soil bacterium is transformed by the incidental acquisition of a 
piece of DNA from some decaying organism. A segment of that DNA may encode a 
domain which confers some natural advantage on the organism and so after the initial 
incorporation of the DNA, in time the lineage may become the major strain or even 
take over the genus. Support in favour of the general process of transfer of genetic 
material between prokaryotes and eukaryotes has been given by Smith et al. (1992) 
and in the case of the transfer of the Fn3 domain a body of evidence exists (Little et 
al., 1994). Interestingly, this evidence includes the fact that the distribution of the Fn3 
domain is at present limited to animals and soil bacteria. Also it may be that soil 
bacteria are especially susceptible to horizontal interkingdom transfer. Enteric bacteria 
are clonal in their evolution whereas soil bacteria have heterogeneous genomes 
reflecting greater amounts of recombination. The organism M.viridifaciens is known 
to be a soil living organism and as such would have had the potential in the past to 
acquire such a mobile module by horizontal gene transfer from a eukaryote.
It is therefore possible that M.viridifaciens has acquired immunoglobulin-like 
and galactose binding modules from eukaryotes such as fungi or animals. Galactose 
oxidase and M.viridifaciens neuraminidase may share a common ancestor in a 
primitive 4-stranded p-sheet, which through gene duplication and functional 





The elucidation of the structure of the 41kDa form of the neuraminidase from 
the non-pathogenic actinomycete M.viridifaciens reveals a remarkable similarity in the 
overall fold of the enzyme to the other neuraminidases characterized so far, in spite of 
a low sequence identity. However, the technique of multiple isomorphous isomorphous 
replacement was required to solve the structure, for despite the high structural 
homology of the 41kDa M.viridifaciens neuraminidase with the other neuraminidases, 
molecular replacement failed to find a solution. This may have been due to the 
differences in orientation of the p strands.
M.viridifaciens secretes the 41kDa form of the enzyme when colominic acid is 
used as an inducer, but secretes the 68kDa form when milk casein is used. It is possible 
that the sialic acid on the casein glycoproteins together with galactose, either on the 
glycoproteins or the lactose “contaminant” often found with casein, is inducing the 
larger form of the enzyme. In addition to a 41kDa domain which shows very little 
difference to the isolated 41kDa enzyme, the 68kDa form of M.viridifaciens
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neuraminidase possess two extra domains, which are very likely to have been acquired 
by horizontal gene transfer from a eukaryote. The linker domain appears to have the 
role of a rigid linker between the other two domains; having a well-packed 
hydrophobic core and cylindrical shape. A function for the galactose binding domain 
has yet to be defined, as is the case for the homologous domain in galactose oxidase. 
However the galactose binding domain may anchor the enzyme to appropriate 
substrates allowing the catalytic domain to cleave sialic acids. Alternatively the 
galactose binding domain may work in concert with the catalytic domain, passing 
appropriate oligosaccharides to the active site through the relative motion of the two 
domains. This could occur around a flexible pivot point consisting of two adjacent 
glycine residues (402 and 403) at the C-terminus of the 41kDa domain (Chapter 9).
Two lectin-like domains were previously identified in the neuraminidase from 
V.cholerae. This suggests that this combination of catalytic and carbohydrate binding 
domains may be common to other members of the neuraminidase family. These 
additional domains may provide additional targets for ligand design in the case of 
pathogenic neuraminidases.
In order to further investigate the role of the additional domains in the 68kDa 
form of the enzyme, se\eral approaches could be taken. Molecular dynamics studies 
could unveil a route, if indeed possible, by which an oligosaccharide could be 
transferred to the active site of the catalytic domain. Alternatively, investigating the 
structure of the enzyme complexed with some non-hydrolysable substrate, such as 
sialic acid linked to galactose via a Sulphur may reveal the function and mobility of the 
galactose binding domain of the 68kDa form of M.viridifaciens neuraminidase.
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Protein methods 
Neuraminidase assay
Neuraminidase activity was assayed using the method of Warren (1959). To 
each tube 0.1ml of the enzyme sample was added, together with 0.1ml of the substrate 
fetuin. Fetuin is obtained from fetal calf serum and consists of N-acetyl neuraminic acid 
attached to an oligosaccharide chain. The solutions were then mixed and placed in a 
water bath at 37°C for about 30 minutes. After this time, 0.1ml of 0.2M sodium 
periodate in 9M phosphoric acid was added, the tubes shaken and allowed to stand at 
room temperature for 20 minutes. 1.0ml of 10% sodium arsenite in a solution of 0.5M 
sodium sulfate-0.1M sulfuric acid was then added and the tubes shaken until a yellow- 
brown colour disappeared. 3ml of 0.6% thiobarbituric acid in 0.5M sodium sulfate was 
added, the tubes shaken, capped with a glass bead and vigorously heated for 15 
minutes in a boiling water bath. The tubes were then removed and placed in cold water 
for 5 minutes, lml of each cooled solution was then transferred to another tube which 
contained lml of cyclohexanone. Each tube was shaken twice and then centrifuged for 
2-5 minutes at 500-1000r.p.m. Ensuring that the upper butanol layer was free of 
turbidity, this layer was carefully pipetted into a cuvette and the absorbance read at a 
wavelength of 549nm in a spectrophotometer. Blanks containing only fetuin, with no 
added enzyme were used to calibrate the machine.
Whilst the enzyme and substrate are incubating, the neuraminidase is catalysing 
the cleavage of the terminal sialic acid attached to the oligosaccharide chain of the
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fetuin, which produces free N-acetyl neuraminic acid (NANA). The addition of sodium 
periodate in 9M phosphoric acid provides a strongly acidic environment which is 
required to obtain a maximal extinction coefficient Strong acid is also probably 
required to remove the acetyl or glycolyl from the amino group before oxidation by the 
periodate. The sodium arsenite is used to desttoy the periodate present. The 
thiobarbituric acid is then coupled with the (3-formylpyruvic acid (oxidized N-acetyl 
neuraminic acid) and the resulting chromophore extracted into cyclohexanone. The 
presence of sodium sulfate in the sodium arsenite and thiobarbituric acid solutions 
leads to a 28% increase in the observed molar extinction coefficient by making the 
extraction of the chromophore by cyclohexanone more complete. The concentration of 
the chromophore, which is equivalent to the concentration of the sialic acid released by 
the neuraminidase can then be calculated by the following procedure:
A=£ cl (Beer Lambert Law)
A= absorption of the chromophore measured at 549nm
£= Molar extinction coefficient of N-acetyl neuraminic acid; =57,000
l=path length (1cm) of cuvette
A
Thus C =  niM  of NANA produced in 30 mins.
57 
A 




=   m M /m in/m g where tot.protein is total
57x30xtot. protein
m g’s of protein in the assay.
Protein estimation
The concentration of protein samples was determined spectrophotometrically 
at 595nm using the method of Bradford (1976). A standard curve was generated for 
each set of protein estimations, using 0 to 20|Hg|Lir1 solutions of Bovine serum albumin.
SDS-polyacrylamide gel electrophoresis
Discontinuous SDS-polyacrylamide gel electrophoresis was performed 
according to the method of Laemmli (1970). A concentration of 10% acrylamide was 
used in the gels.
Gel filtration
(As described in Chapter 2)
Anion exchange
(As described in Chapter 2)
Crystallizations
The method of hanging drop vapour diffusion was employed in all cases 
(Mcpherson, 1990). Cover slips were silanised before use. All protein samples were 
concentrated to 10-12mg/ml using the centricon concentrators prior to crystallization
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trials. The appropriate volumes of protein sample and precipitant containing buffer 
were added to each coverslip, which was then inverted and placed over a well in a 
Limbro tissue culture plate. Each well in use, contained 1ml of the buffer and 
precipitant solution. An air tight seal between the coverslip and the well was achieved 
by placing a thin layer of grease around the rim of the well.
Materials
Crude native M.viridifaciens neuraminidase supplied as an ammonium sulfate 
precipitate from a culture filtrate, was a generous gift from Dr. Takayuki Uwajima, 
Tokyo Research Laboratories, Kyowa Hakko Kogyo Co. Ltd, Tokyo, Japan. 
Additional crude recombinant M.viridifaciens neuraminidase, used to produce 
additional 41kDa crystals, was a generous gift from Dr. Mamoru Hasegawa, Tokyo 
Research Laboratories, Kyowa Hakko Kogyo Co. Ltd, Tokyo, Japan.
General reagents were obtained from BDH, SIGMA or FISONS. 
Neuraminidase from C.perfringens (used to verify the validity of the neuraminidase 
assay) was obtained from Boehringer Manheim.
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Diffraction by a set of planes
W.L. Bragg showed that the angles at which diffracted beams emerge from a 
crystal can be computed by treating diffraction as if it were from sets of equivalent 
parallel planes of atoms in a crystal. Diffraction occurs from parallel planes present in 
each unit cell of the crystal.
The unit cell is the smallest and simplest volume element that is completely 
representative of the whole crystal. The array of points at the vertices of unit cells is 
known as the lattice. The dimensions of the unit cell are designated by six numbers: the 
lengths of the three unique edges a, b and c; and three unique angles a , (3 and y. There 
are seven different classes of unit cell, depending on equivalences in the unit cell 
dimensions. A cell in which a ^ b *c and a  * (3 *  y is termed triclinic (fig. 2.1). If a *  b 
*c, a  = y = 90° and |3 > 90°, the cell is monoclinic. If a = b * c, a  = (3 = 90° and y = 
120°, the cell is hexagonal or trigonal. For cells where a  = |3 = y = 90°and a = b = c, 
the cell is cubic; if a = b ^ c, the cell is tetragonal; and if a ^  b *c, the cell is 
orthorhombic.
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Fig. 2.1 The Triclinic unit cell.
The 41kDa M.viridifaciens neuraminidase crystals are orthorhombic and the 
68kDa M.viridifaciens neuraminidase crystals are monoclinic.
Regularly spaced planes that can be drawn through lattice points in the crystal 
are effectively sources of diffraction. The Miller indices hkl identify a particular* set of 
equivalent, parallel planes and specify the number of planes that exist per unit cell in 
the a, b, c directions respectively. The unit cell is in real space, whereas the diffraction 
pattern is in reciprocal space. The reciprocal lattice, with unit cell lengths a*, b*and c*, 
is related to the lattice in real space for a unit cell where a  = (3 = y = 90° by a* = 1/a, 
b* = 1/b and c* = 1/c. The Miller indices are used to designate individual reflections in 




Bragg demonstrated that a set of parallel planes with Miller indices hki and 
interplanar spacing dhki produces a diffracted beam when X-rays of wavelength of X 
impinge on the planes at an angle 0 and are reflected at the same angle, only if 0 meets 
the condition:
nA, = 2d hki sin0 where n is an integer.
Fig. 2.2 illustrates the conditions necessary to produce a diffracted beam. Two rays Ri 
and R.2 are reflected from from two parallel planes of lattice points with interplanar 
spacing dhki at an angle 0. The additional distance travelled by the more deeply 
penetrating ray R2 is 2dhki sin0.
Fig. 2.2 Bragg’s law in real space. Interplanar spacing = dhki- Two rays Ri and R2 are 
reflected at an angle 0 by two parallel planes of lattice points, sin 0 = BC/AB. The 






Bragg’s Law can also be applied in reciprocal space. Fig. 2.3 shows an a* b* 
plane of a reciprocal lattice, with an X-ray beam (X O) impinging on the crystal along 
this plane. The circle has radius 1A, with its centre C on XO and passing through O.
1A  is the wavelength of the X-rays in reciprocal space. If the crystal is rotated about 
O, the reciprocal lattice is also rotated around O , successively bringing reciprocal 
lattice points such as P and Pv into contact with the circle. The angle PBO is 0 and 
hence:
OP OP
sin 0 = = --------
BO 2 I X
1
and therefore 2  sin 0 = X
OP
Since P i s a  reciprocal lattice point, the length of OP is 1/cUu and this gives: 
nA, = 2dhki sin0
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Fig. 2.3 Bragg’s Law in reciprocal space. When the crystal is rotated so that a 
reciprocal lattice point such as P comes in contact with the circle of radius 1A-, 
Bragg’s law is satisfied and ray R emerges from the crystal. Reciprocal lattice point P' 
does not intersect the circle.
The Fourier series and Fourier transform
A simple wave can be described by a periodic function such as the equations:
f ( x )= F  cos 2n(hx. + a)
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or
/  (x) = F sin 2n(hx + a)
In these functions, f(x) specifies the vertical height of the wave at any 
horizontal position x. along the wave. The variable * and the constant a  are angles 
expressed in fractions of the wavelength. The constant F specifies the amplitude of the 
wave and h the wavelength or frequency, a  is the phase of the wave.
Any wave can be described as the sum of simple waves. This sum is known as a 
Fourier series and a Fourier series of n terms can be written using the first simple wave 
equation above as follows:
f ( x )  = Fo cos 2ti(0a: + (Xo)
-f
F] cos 2n(lx + (Xi)
+
F2 c o s  27t(2* + a 2)
+
+
Fn cos 27t(nx + a,,)
or
a
f(x) = ^  Fh  cos 2% (hx + a/7)
/7=0




fix)  = ^  F*[cos 2% (hx) + i sin 2ti ihx)] 
h=0
From complex number theory: cos 0 + i sin 0 = e10 so the Fourier series becomes:
fix)  = 2 ,  r  h e  
h
This is a Fourier series for a one dimensional wave. In three dimensions this 
becomes:
^  r-p 2ni{hjc+ky+lz) 
fix , y ,z)=  2^  r  hki e  
hki
Fourier showed that for a function f(x), there is another function F(h) such
that:
- f - o o
f  2 m ( h x )
F(h) = J f i x ) e  dx
— o o
F(h) is the Fourier transform off(x) and a\sof(x) is the transform of F(h). In 
other words the above Fourier transform operation is reversible:
+ o o
f  - 2 t c i ( h x )
fix) = J Fih)e dh 
Again though we are interested in the Fourier series in three dimensions:
F(hkl)= f f(xyz)e2*i{hx*ky*'z)dx dy dz 
xyz
and fixyz) = J F ihkt)t2ldilix+ky+lz)dh dkdl 
hki
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A structure factor, which describes a given reflection, can also be expressed as 
a Fourier series. A single term in this series is called an atomic structure factor f hki and 
represents the contribution of the single atom j to reflection hki:
The term fi is the scattering factor of atom j  and is a function that treats the atom as a 
sphere of electron density. As a result the function is different for each element, since 
each element has a different number of electrons. Xj, yj and z-} are the coordinates of 
atom j  in the unit cell.
The structure factor Fhk\, for a unit cell containing n atoms, is the sum of 
diffractive contributions from all atoms in the unit cell, or in other words the sum of all 
the individual//,*/ values. The Fourier series for n terms is given by:
Fhki may also be written as the sum of contributions from each volume element 
of electron density in the unit cell:
fhki - f i e
2  Jzi( hxj+kyj+lzj )
n 2ni (hxj+kyj+lzj)
Fhki ~ J ,  f j €




27u(/ly + ky + Iz)
dV
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Here, F/lki is the Fourier transform of p(x y z) on the set of real lattice planes 
(Mi). V is simply the unit cell volume, i.e. the integration is over all values of x, y and z 
in the unit cell.
Since the Fourier transform operation is reversible, the electron density can be 
represented as the transform of the structure factors, thus:
Here each Fhki is a structure factor, itself a Fourier series, describing a specific 
reflection in the diffraction pattern. Fhki is a periodic function, possessing amplitude, 
frequency and phase. The frequency is that of the X-ray source. The amplitude of Fhki 
is obtained from the diffraction pattern, since the amplitude is proportional to the 
square root of the intensity of the measured reflection (//,*/). However the phase of Fhki 
is unknown, since this is lost when the X-rays are diffracted. This is known as the 
phase problem and is the fundamental problem to be solved in macromolecular 
crystallography.
Structure factors may be represented as complex vectors (a + ib). The length of 
this vector represents the amplitude of the structure factor and the phase of the 
structure factor is represented by the angle a  that the vector makes with the real axis, 
when the origin of the vector is placed at the origin of the complex plane. This is 
illustrated in fig. 2.4.
■2ni(Ivc+ky+lz)l
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cos a  = and sin a  = ----
I FI I FI
and therefore:
IAI = IFI cos a  and IBI = IFI sin a
Expressing F in the form A + iB;
F = IAI + ilBI -- IFI ( cos a  + i sin a  )
Since cos a  + i sin a  = e1 a 
F = IFI eia
At present we have the following electron density equation:
1 —• 2Tii(hx+ky+lz)
p (x y z) = —  Z ^ r  hki e
y  hki
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If we insert F = IFI e10t into the above equation we obtain:
V I  Z7 I i^OLhkl —2Ki(hx+ky+lz)
p (x y z) = 2^i I * hkl\ C C
V  hki
The phase angle in radians is given by: a  = 271a'. This simplifies the 
exponential terms to:
 ^ V  I z? I ~27ticc'hki —2ni(hx+ky+lz)
p (x y z) = —  2^  I r  hki I 6  C
V  hki
Finally, if we add the exponents:
■v"'* | r~i I -2 n i(hx+ky+lz-a'hid)
p ( x y Z) = —  2jFhki\ e
V  hki
This final electron density equation gives the desired electron density as a 
function of the known amplitudes IFI and the unknown phases a'hki of each reflection.
Estimation of the unknown phases 
(a) Isomorphous replacement
Each atom in the unit cell contributes to every reflection in the diffraction 
pattern. Hence if one or a very small number of atoms were added to identical sites in 
all unit cells of a crystal, changes would arise in the diffraction pattern as a result of the 
additional contributions of the added atom. This slight perturbation in the diffraction 
pattern caused by the added atom can be used to obtain initial estimates of phases. The 
added atom must be a strong diffractor, i.e. a heavy atom, in order for these changes in 
the intensities of the reflections to be measured.
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If Fp is the structure factor of a native reflection, FPH is the structure factor of 
the corresponding derivative reflection and FH is the structure factor for the heavy 
atom alone, then because the diffractive contributions of atoms are additive vectors the 
following relationship holds:
F?h -  Fh + Fp 
Fig. 2.5 illustrates the above relationship in vector form:
Fig. 2.5 The phase triangle: the structure factor FPH is the sum of contributions from 




The position of the heavy atoms in the unit cell may be calculated using a 
Fourier series called the Patterson function P(u,v,w). The Patterson synthesis can be 
constructed from intensity measurements, even though no phase information is 
available. The amplitude of each term in the Patterson function is the square of one 
structure factor, which is proportional to the measured reflection intensity. The 
difference Patterson function for the heavy atoms alone has amplitudes AF2 = (IF r pI - 
IFpl)2. Thus the difference Patterson function is:
l  ^
AP (u v w) = -  X  AF h k i e (hu +kv +lw)
V hki
From the location of the heavy atoms, the vector FH can be calculated and 
therefore the phase of the native protein alone (aP) can be solved. In the vector 
diagram of fig. 2.5, a P can be determined from the cosine law:
CCp =  CCh  +  C O S '1
(  p 2 _  p 2 _  p 2 A
PH_________ P__________H_
V 2FpFh j
-  aH ±a'
As can be seen from the above calculation of Otp, there are two possible values 
for OCp which cannot be distinguished with one isomorphous derivative. In addition the
initial phase estimates are inaccurate due to errors which arise as a result in 
measurement of amplitudes for example. These errors result in lack of closure, where 
the phase triangle does not close. In order to improve the qualtiy of the phase 
estimates and to resolve the phase ambiguity which arises with one derivative, at least 
one further derivative is usually required.
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The Harker construction shown in fig. 2.6 best explains how this phase 
ambiguity is overcome. In fig. 2.6 (a) the vector -FH is placed at the origin and a circle 
of radius IFHpl is drawn, centred on the head of vector -FH. Next a circle of radius IFPI 
is added, centred at the origin. The equation FP = FPH - FH is only true at points where 
the two circles intersect. Thus the correct phase angle a P is either that for the vector
F a or F b . Fig. 2.6 (b) shows the phase determination using a second heavy-atom
p  p
derivative. FH is the structure factor for the second heavy atom. The radius of the 
smaller circle is IF hpI, the amplitude of F hp for the second heavy atom derivative. For
this derivative, FP = F HP - F H. In fig. 2.6 (c), the phase circles from fig’s 2.6 (a) and
c a
(b) are superimposed, showing that the correct phase angle is that for F and F 
which are identical.
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Fig. 2.6 Harker circle constructions (a) Vectors from the origin to intersections of 
the two intersections are solutions to Fp = Fph - Fh (b) A second heavy atom
d  C
derivative indicates two possible phases; F or F (c) Superposition of the previous 








Various statistical parameters are used to judge the quality of the phase 
estimates, such as figure of merit, lack of closure errors and various R-factors, and to 
weight the Fourier syntheses towards the more accurately determined phases, whilst 
culling or down-weighting those phases that are more questionable. The best electron 
density map obtained therefore, is that with centroid phases (PHIBEST) and weighted 
by FOM (figure of merit - Chapter 4). Due to errors in measurements of intensities, 
lack of isomorphism and incorrect heavy atom positions, the three phase circles in fig. 
2.6 (c) will not intersect in one place in practice and the phase determination will be 
ambiguous. Crick and Etlow have given a thorough treatment of errors in the method 
of isomorphous replacement (Blow & Crick, 1959) and best choice of weights to use 
in the calculation of the electron density map.
Anomalous scattering also provides a means of obtaining phase information. 
This is where Friedel’s Law breaks down and the reflections hki and -h-k-1 are no 
longer equal in intensity. Anomalous scattering arises when the added heavy atom’s 
absorption edge is near the X-ray wavelength.
(b) Molecular replacement
The initial determination of phases by the technique of molecular replacement is 
often attempted if the structure of a similar or homologous macromolecule is known. 
This homologous structure is known as the search model and is placed in the unit cell 
of the target crystal and rotated and translated in order to obtain the best agreement 
between the observed and calculated diffraction data. The rotation and translation
2 0 2
searches for the best orientation and position of the search model are generally 
performed separately, due to limitations in computing power.
A second molecular replacement str ategy used to gain phase information is the 
search for the orientation of non-crystallographic symmetry elements in the asymmetric 
unit of the crystal. Using this powerful technique, electron density maps have been 
improved by “averaging” around local symmetry elements. The former molecular 
replacement strategy will be discussed in more detail here.
The Rotation function
Tire rotation function as developed by Rossmann and Blow (1962) defined a 
Patterson overlap function as the product of two Pattersons integrated over a volume 
containing only self-vectors, where:
R[£i] = j Po (u) . Pc (u ' ) d U  
U
In the above equation: 
u' = | Q.] u
£2 = rotation matrix
P0 (u) = value of observed Patterson function at point u
Pc (u') = value of calculated Patterson function at point u'
U volume over which matching is expected
P (u) can be expanded in terms of structure factor amplitudes:
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1 —  2
P (u) = y ,  I F(hkl)l exp(-27ti(hu + kv + lw))
y  hki
As a result, this simplifies R[£2] to:
R[Q] = I F(h)|2 1 F(p)|2 Ghh'
V h P
In this equation:
IF(h)l = observed structure factor amplitudes
IF(p)l = calculated structure factor amplitudes
IT = [Q] p
Ghh' = interference function. This contains information about the rotation in
lattice vector IT
This overlap function would be expected to give a high correlation when the 
Pattersons of the search model and unknown molecule are superimposed.
Crowther (1972) has expanded the Pattersons in the rotation function in terms 
of spherical harmonics. By representing the Patterson density within a spherical volume 
as a function of normalized spherical Bessel functions and normalized spherical
2
harmonics, rather than Cartesian Fourier components I F(h)l , it was possible to use 
fast Fourier transforms to calculate values of the Rossmann and Blow function. This
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resulted in a decrease in the calculation time, but at the expense of limiting the volume 
of integration to being spherical.
Navaza (1987) implemented the enhancement of rotation peaks in the AMoRE 
package, by skipping low angular resolution contributions. The formulation of the 
rotation function is essentially that of Crowther, but uses numerical integration instead 
of Fourier-Bessel expansions in tire radial variable. Important numerical instabilities 
were removed by the use of a new algorithm to calculate the reduced rotation matrices 
(Navaza, 1990).
The Translation function
Once the search model has been placed in the correct orientation by a correct 
solution to the rotation function, the translational parameters are obtained for 
positioning the model inside the unit cell, using the translation function. The T2 
function of Crowther and Blow (1967) is a Patterson overlap function. This function 
calculates a three dimensional Patterson overlap function using the cross-vectors 
(intermolecular vectors) contained in the unit cell. The T2 function has the form:
T2 (t) = J (Po(u) -  Pm(u)) . (Pc(u, t) - Pm(u)) du
V
In this equation:
P o  (u) = Patterson of unknown structure from IF0l’s
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P m  (u) = sum of separate self-Pattersons of n asymmetric units of the
known structure in their correct orientations, obtained from model IFI’s.
P c  (u, t) = Patterson of the complete unit cell of the trial structure
consisting of x asymmetric units of known structure in their correct orientation and 
position.
V = Unit cell volume
In order to obtain a large correlation from the overlap function, the 
translational components of the search model (t) are varied. The overlap function can 
also be expressed in terms of structure factors in reciprocal space:
T(2) = ^  (Fo (h) -Fm (h)) . (Fc (h, t) - Fm (h))
"h
The output from the T(2) translation function is a list of modified Fourier 
coefficients which are then used to calculate a three dimensional translation function 
map using the fast Fourier transform (Ten Eyck, 1973).
Refinement
Refinement is the process of altering the parameters of the model in order to 
improve the agreement between the model and the experimental observations. These 
parameters are in the most part the positions (xj, y\, zj) and the thermal parameters ( B j )  
of the j atoms. A function which describes the discrepancy between the amplitudes of
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the observed reflections and the values calculated from the model parameters is the 
function to be minimized. There are a variety of refinement packages available, 
implementing different methods of refinement, including X-PLOR (Brunger, 1988) and 
TNT (Tronrud etal., 1987).
The X-PLOR energy function
In general, the energy function to be minimized in the refinement process can 
be represented by the equation:
'empirical
where Ex.ray = X w  (I F0 I - IFC I)", the X-ray pseudo energy term.
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The term (1), describes the covalent bond energy, where r is the actual bond 
length, k is an energy constant and r0 is equilibrium constants. Term (2) describes the 
bond angle energy, where ke and kub are energy constants and 0o and rub are equilibrium 
constants. 0 is the value of the angle and i*i3 is the distance between the first and third 
atom defining the angle. The term (3) describes energy terms involving dihedral and 
improper angles. (J) is tire torsion angle, k^ , are energy constants, n are periodicities, m 
are multiplicities and 5 are the phase shifts. The explicit hydrogen-bond energy term,
E h  b o n  is given by the term in (4). The atoms AA, A, H and D are the receptor 
antecedent, acceptor, hydrogen and donor heavy atom respectively, where i, j and m 
are positive integers and SW is the switching function, which has the form:
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0 if R > Roff
S W ( R ,  R o n , R o f f )  -  < ifR 0fif >R >Ron
1 if R < Ron
The switching function SW defined above, maintains a continuous and smooth 
function to the cutoff point so that derivatives are well defined at the cutoff point The 
van der Waals function is given by term (5). The first equation provides the truncation 
option, the second the switched option and the third the repel option. H is the heavy- 
side function and SW is the same switching function as described above. The van der 
Waals function is described by a Lennard-Jones potential in both the truncated and 
switched option. Term (6) gives the electrostatic function. The first equation is for 
pure truncation, the second gives the shifted option, the third provides for the 1/R 
option and 0 gives the repel option. These options are used to truncate the electrostatic 
potential; because of the need to limit the number of pair interactions and to avoid 
discontinuities in the forces. Intramolecular interactions are provided for by term (7). 
The summation is over the individual nonbonded interaction energies for pairs of 
atoms (i, j) within the current molecular structure. In order to reduce computational 
time, there is a cutoff, which is the distance Rij at which the energy becomes zero, 
given by R0ff, for both switched and shifted nonbonded options. Term (8) computes the 
crystallographic symmetry interactions between the molecule(s) located in the 
asymmetric unit and all symmetry-related molecules (i.e. intermolecular interactions). 
The first equation computes symmetry interactions for packing van der Waals forces 
and the second for packing electrostatic energies. The final term (9) computes the
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interaction between non-crystallographically related molecules, using the/vow and 
/ft fc functional forms.
Stages in the X-PLOR refinement
Fig. 2.7 summarizes the following stages in the X-PLOR refinement. The first 
stage in the X-PLOR refinement was GENERATE. GENERATE adds the nitrogen 
hydrogens and oxygen hydrogens to the model, prior to a round of refinement and 
prepares a molecular structure file, which contains information such as bond angles, 
atom names and types and hydrogen bonding terms. CHECK determines the ideal 
weight WA between E x r e f  and E e m p i r ic a l  and also checks the initial R value for the 
structure. The weight is determined by running a brief molecular dynamics calculation 
in the absence of E x r e f  and then comparing the norm of the gradient of E e m p i r ic a l  and 
the norm of the gradient of E x r e f - PREPSTAGE uses the weight calculated in CHECK 
and performs several cycles of minimization on the model in order to relieve strain or 
bad contacts. PREPSTAGE is a typical least squares refinement, where the function to 
be minimized is X  w  (IF obsl-IF caicJ)2 ; simultaneously with restrictive stereochemical 
terms. However, as with all least squares only the nearest local minimum from the 
starting coordinates will be reached. Therefore PREPSTAGE was followed by 
refinement in SLOWCOOL. SLOWCOOL, or simulated annealing involves refinement 
using the principles of molecular dynamics. Molecular dynamics consists of 
simultaneously solving Newton’s equations of motion for all atoms under the influence 
of a potential derived from empirical stereochemical terms and observational restraints. 
In SLOWCOOL, the initial temperature of the system is set to typically 2000K, in 
order to apply kinetic energy to the system. Random velocities, whose distribution is a
211
function of the temperature, are applied to all the atoms. This results in a new position 
and velocity for each atom a very small time step later. The high kinetic energy of the 
system, derived from the high initial temperature, allows the overcoming of energy 
barriers and a large number of conformations can be explored. In the SLOWCOOL
algorithm, the temperature of the system is gradually reduced from 2000K in the
hope of finding the global energy minimum.
SLOWCOOL ouputs a refined set of coordinates and its R-factor. The R-factor 
is defined by the equation:
I I I  F obs I -  I F c a l c I I
R= —----------------------
L I F o b s I
The R-factor is a common method of monitoring the progress of a refinement. 
The better the agreement between the structure factor amplitudes from the observed 
reflections and those calculated from the model, the lower the R-factor will be and 
presumably the better the model. R-values approaching 12% have been achieved for 
the most extensively refined models with resolution better than 2A and R-values in the 
vicinity of 60% indicate a structure that does not fit the data any better than does a 
random one.
Despite the stereochemical restraints imposed in the refinement process it is 
still possible to overfit the diffraction data, particularly if the observation to parameter 
ratio is poor. Thus an incorrect model can be refined to a fairly good R value as past 
examples have shown (Branden & Jones, 1990). An unbiased test of the accuracy of an 
atomic model was therefore proposed. A statistical quantity Rfree was defined that
212
measures the agreement between the observed and calculated structure factor 
amplitudes for a “test” set of reflections that is omitted in the refinement and modelling 
process (Brunger, 1992). Examples have shown that there is a high correlation 
between the accuracy of the phases calculated for the atomic model and the Rfree 
(Bmnger, 1992). The unique set of observed reflections is separated into a “test” set T 
and a “working” set A and the free R value to be computed is:
X ( h k l )  s  t \ I F o b s o ik l) !— kl F calc(hk l)! I
y  (hkl) e  r lF o b s (h k i) !
T is omitted in the modelling and refinement process and the crystallographic 
residual to be minimized is:
R A = X  (I Fobs(hkl)l—kl Fcalc(hkl)l)
(hkl)eA
Temperature factor refinement
Assuming that the occupancies for the set of coordinates are correct, Bj is a 
measure of the thermal motion at atom j. In the simplest case of purely harmonic 
thermal motion of equal magnitude in all directions, or isotropic vibration, Bj has the 
following relationship to magnitude of vibration:
B, = 8n2 {u2 } = 79{u2 }j j  j
213
where {u } is the mean-square displacement of the atom from its rest position in A2.
In order to refine the temperature factors (B-factors) there is an essential requirement 
for a high observation to parameter ratio; i.e. a high completeness of data at a high 
resolution. Isotropic B-factors can be refined at a resolution of 2.7A or better, with a 
good completeness of data. However, in order to refine B-factors anisotropically 
requires six parameters per atom and therefore a very high resolution with a high 
completeness of data is required.
Fig. 2.7 Summary of the refinement stages employed in X-PLOR.
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